{"id":3804,"date":"2025-07-07T11:38:53","date_gmt":"2025-07-07T06:08:53","guid":{"rendered":"https:\/\/regisdigitals.com\/client\/Sunact\/?page_id=3804"},"modified":"2026-01-11T09:51:29","modified_gmt":"2026-01-11T04:21:29","slug":"dr-prof-vijay-patil-founder-and-pioneer-of-sunact-advanced-cancer-therapies","status":"publish","type":"page","link":"https:\/\/regisdigitals.com\/client\/Sunact\/dr-prof-vijay-patil-founder-and-pioneer-of-sunact-advanced-cancer-therapies\/","title":{"rendered":"Dr. (Prof.) Vijay Patil &#8211; Founder and Pioneer of SunAct &#8211; Advanced Cancer Therapies"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"3804\" class=\"elementor elementor-3804\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-81496e7 e-flex e-con-boxed e-con e-parent\" data-id=\"81496e7\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-393150a e-con-full e-flex e-con e-child\" data-id=\"393150a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d3dd6ed elementor-widget elementor-widget-heading\" data-id=\"d3dd6ed\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h6 class=\"elementor-heading-title elementor-size-default\">Co-founder, SUNACT<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f76f71a elementor-widget elementor-widget-heading\" data-id=\"f76f71a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h6 class=\"elementor-heading-title elementor-size-default\">Specialist in Solid Tumors &amp; Advanced Cancer Therapies<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-05680e4 elementor-widget elementor-widget-heading\" data-id=\"05680e4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Dr. (Prof.) Vijay Patil<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1b57196 e-grid e-con-full e-con e-child\" data-id=\"1b57196\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-774f1f7 e-con-full e-flex e-con e-child\" data-id=\"774f1f7\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3096059 elementor-widget elementor-widget-image\" data-id=\"3096059\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"800\" height=\"927\" src=\"https:\/\/regisdigitals.com\/client\/Sunact\/wp-content\/uploads\/2025\/09\/1-1-1-scaled-e1758691701360-884x1024.webp\" class=\"attachment-large size-large wp-image-5445\" alt=\"\" srcset=\"https:\/\/regisdigitals.com\/client\/Sunact\/wp-content\/uploads\/2025\/09\/1-1-1-scaled-e1758691701360-884x1024.webp 884w, https:\/\/regisdigitals.com\/client\/Sunact\/wp-content\/uploads\/2025\/09\/1-1-1-scaled-e1758691701360-259x300.webp 259w, https:\/\/regisdigitals.com\/client\/Sunact\/wp-content\/uploads\/2025\/09\/1-1-1-scaled-e1758691701360-768x890.webp 768w, https:\/\/regisdigitals.com\/client\/Sunact\/wp-content\/uploads\/2025\/09\/1-1-1-scaled-e1758691701360-1325x1536.webp 1325w, https:\/\/regisdigitals.com\/client\/Sunact\/wp-content\/uploads\/2025\/09\/1-1-1-scaled-e1758691701360.webp 1654w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4bcf5c6 e-con-full e-flex e-con e-child\" data-id=\"4bcf5c6\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3e55868 elementor-widget elementor-widget-heading\" data-id=\"3e55868\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h5 class=\"elementor-heading-title elementor-size-default\">Transforming cancer care through innovation, accessibility, and compassion.<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-12ff882 e-con-full e-flex e-con e-child\" data-id=\"12ff882\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2a3fd47 elementor-widget elementor-widget-heading\" data-id=\"2a3fd47\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h6 class=\"elementor-heading-title elementor-size-default\">About Dr. Patil<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-89d0e87 elementor-widget elementor-widget-text-editor\" data-id=\"89d0e87\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">Dr. (Prof.) Vijay Patil is a distinguished medical oncologist with over 2 decades of clinical and research experience, specializing in the management of solid tumors and the development of next-generation cancer therapies. He has authored more than 750 peer-reviewed publications in leading international journals, including the Journal of Clinical Oncology, The Lancet Global Health, Oral Oncology, Cancer, Cancer Cell, and ASCO publications.<\/span><\/p><p><span style=\"font-weight: 400;\">He completed his MBBS from Grant Medical College &amp; KEM Hospital, Mumbai, in 2006, completed his MD in Radiotherapy at PGIMER, Chandigarh, in 2009 with the Kataria Gold Medal, and earned his DM in Medical Oncology from Tata Memorial Centre, Mumbai, in 2013 with a Gold Medal.<\/span><\/p><p><span style=\"font-weight: 400;\">Through his clinical expertise and research leadership at SunAct, Dr. (Prof.) Patil continues to contribute to advancements in oncology and strives to improve outcomes for patients worldwide.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-34e2583 elementor-widget elementor-widget-elementskit-accordion\" data-id=\"34e2583\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"elementskit-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"ekit-wid-con\" >\n        <div class=\"elementskit-accordion accoedion-primary\" id=\"accordion-69e0891c35504\">\n\n            \n                <div class=\"elementskit-card \">\n                    <div class=\"elementskit-card-header\" id=\"primaryHeading-0-34e2583\">\n                        <a href=\"#collapse-bad4b4369e0891c35504\" class=\"ekit-accordion--toggler elementskit-btn-link collapsed\" data-ekit-toggle=\"collapse\" data-target=\"#Collapse-bad4b4369e0891c35504\" aria-expanded=\"false\" aria-controls=\"Collapse-bad4b4369e0891c35504\">\n                            \n                            <span class=\"ekit-accordion-title\">Qualifications &amp; Academic Background<\/span>\n\n                            \n                                <div class=\"ekit_accordion_icon_group\">\n                                    <div class=\"ekit_accordion_normal_icon\">\n                                        <!-- Normal Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"icon icon-down-arrow1\"><\/i>                                    <\/div>\n\n                                    <div class=\"ekit_accordion_active_icon\">\n                                        <!-- Active Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"icon icon-up-arrow1\"><\/i>                                    <\/div>\n                                <\/div>\n\n                            \n                                                    <\/a>\n                    <\/div>\n\n                    <div id=\"Collapse-bad4b4369e0891c35504\" class=\" collapse\" aria-labelledby=\"primaryHeading-0-34e2583\" data-parent=\"#accordion-69e0891c35504\">\n\n                        <div class=\"elementskit-card-body ekit-accordion--content\">\n                            <p>He completed his MBBS from Grant Medical College &amp; KEM Hospital, Mumbai, in 2006, completed his MD in Radiotherapy at PGIMER, Chandigarh, in 2009 with the Kataria Gold Medal, and earned his DM in Medical Oncology from Tata Memorial Centre, Mumbai, in 2013 with a Gold Medal.<\/p>                        <\/div>\n\n                    <\/div>\n\n                <\/div><!-- .elementskit-card END -->\n\n                \n                <div class=\"elementskit-card \">\n                    <div class=\"elementskit-card-header\" id=\"primaryHeading-1-34e2583\">\n                        <a href=\"#collapse-959293f69e0891c35504\" class=\"ekit-accordion--toggler elementskit-btn-link collapsed\" data-ekit-toggle=\"collapse\" data-target=\"#Collapse-959293f69e0891c35504\" aria-expanded=\"false\" aria-controls=\"Collapse-959293f69e0891c35504\">\n                            \n                            <span class=\"ekit-accordion-title\">Work Experience<\/span>\n\n                            \n                                <div class=\"ekit_accordion_icon_group\">\n                                    <div class=\"ekit_accordion_normal_icon\">\n                                        <!-- Normal Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"icon icon-down-arrow1\"><\/i>                                    <\/div>\n\n                                    <div class=\"ekit_accordion_active_icon\">\n                                        <!-- Active Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"icon icon-up-arrow1\"><\/i>                                    <\/div>\n                                <\/div>\n\n                            \n                                                    <\/a>\n                    <\/div>\n\n                    <div id=\"Collapse-959293f69e0891c35504\" class=\" collapse\" aria-labelledby=\"primaryHeading-1-34e2583\" data-parent=\"#accordion-69e0891c35504\">\n\n                        <div class=\"elementskit-card-body ekit-accordion--content\">\n                            <p><b>Overview<\/b><\/p><p><span style=\"font-weight: 400\">Over the course of his career, Dr. (Prof.) Vijay Patil has cared for more than 12 lakhs patients and contributed to the development of new treatment approaches and clinical criteria in oncology. He has also played an active role in national and international clinical trials, helping to bring emerging therapies into practice.<\/span><span style=\"font-weight: 400\"><br \/><\/span><span style=\"font-weight: 400\">His treatment experience spans:<\/span><\/p><ul><li><span style=\"font-weight: 400\">Chemotherapy \u2013 5,00,000+ patients<\/span><\/li><li><span style=\"font-weight: 400\">Metronomic Chemotherapy \u2013 1,50,000+ patients<\/span><\/li><li><span style=\"font-weight: 400\">Targeted Therapies \u2013 1,00,000+ patients<\/span><\/li><li><span style=\"font-weight: 400\">Immunotherapy \u2013 10,000+ patients<\/span><\/li><li><span style=\"font-weight: 400\">CAR T-Cell Therapy \u2013 among the early adopters in India, involved in patient selection, administration, and follow-up care.<\/span><\/li><\/ul><p><span style=\"font-weight: 400\">Through a combination of clinical experience and ongoing research, he continues to contribute to advancements in cancer treatment for patients across the country.<\/span><\/p><p><b>Head and Neck Cancer<\/b><\/p><ul><li><b>Low-dose immunotherapy:<\/b><span style=\"font-weight: 400\"> Developed a low-dose immunotherapy regimen that is an alternative standard of care, bringing treatment costs down by more than 90%.<\/span><\/li><li><b>Double metronomic chemotherapy:<\/b><span style=\"font-weight: 400\"> Conceptualized an oral, low-cost regimen that was proven to be more effective and have fewer side effects than the previous intravenous standard treatment. This regimen has since entered practice guidelines.<\/span><\/li><li><b>Triple metronomic chemotherapy:<\/b><span style=\"font-weight: 400\"> Developed an alternative regimen to immunotherapy for a subset of platinum-refractory head and neck cancer patients, which proved similarly effective at under 1% of the cost. The results were published in the Journal of clinical oncology.<\/span><\/li><li><b>3 weekly cisplatin:<\/b><span style=\"font-weight: 400\"> A phase 3, randomized study provided the first robust data on the optimal schedule for cisplatin usage with radiation.<\/span><\/li><li><b>Nimotuzumab:<\/b><span style=\"font-weight: 400\"> A randomized phase 3 study on over 500 patients proved the efficacy of adding the novel drug Nimotuzumab to cisplatin.<\/span><\/li><li><b>Docetaxel:<\/b><span style=\"font-weight: 400\"> A large phase 3 study proved that adding Docetaxel as a radiosensitizer to radiation improved outcomes in cisplatin-ineligible patients.<\/span><\/li><li><b>Neoadjuvant chemotherapy for organ preservation:<\/b><span style=\"font-weight: 400\"> A randomized study proved that giving neoadjuvant chemotherapy could shrink jaw tumors, allowing for surgical removal without having to remove the jaw, thus preserving it for the patient.<\/span><\/li><li><b>Neoadjuvant chemotherapy for borderline resectable cancers:<\/b><span style=\"font-weight: 400\"> Developed a strategy where neoadjuvant chemotherapy shrinks advanced tumors enough for them to be operated on, thus prolonging patients' lifespan.<\/span><\/li><li><b>Other Head and Neck Cancer Treatments:<\/b><span style=\"font-weight: 400\"> Has experience treating Thyroid cancer, Salivary gland tumors, Skull base tumors, and NUT midline carcinomas with various systemic therapies. He also developed the neoadjuvant regimen of Cisplatin &amp; etoposide in sinonasal malignancies.<\/span><\/li><\/ul><p><span style=\"font-weight: 400\"><br \/><\/span><b>Thoracic Tumours<\/b><\/p><ul><li><b>EGFR mutated tumors:<\/b><span style=\"font-weight: 400\"> A phase 3 study proved that an oral tablet of gefitinib was superior to the prevalent IV first-choice treatment. A subsequent study showed that adding IV chemotherapy to the oral tablet was even better, and this is now an accepted standard treatment guideline.<\/span><\/li><li><b>Low-dose gemcitabine:<\/b><span style=\"font-weight: 400\"> Conceptualized and proved an alternative treatment equally effective to the standard treatment for a type of lung cancer, while being 25% cheaper.<\/span><\/li><li><b>Erlotinib maintenance:<\/b><span style=\"font-weight: 400\"> Proved that an oral drug gave a similar quality of life as the currently used IV drug for maintenance in a lung cancer, providing a cost-effective alternative that reduced hospital visits.<\/span><\/li><li><b>Immunotherapy in NSCLC:<\/b><span style=\"font-weight: 400\"> Helped establish the safety and efficacy of immunotherapy in lung, esophageal, and other cancers in India.<\/span><\/li><li><b>Targeted therapies:<\/b><span style=\"font-weight: 400\"> Has one of the largest published experiences with numerous targeted therapies for various mutations in lung and other cancers.<\/span><\/li><\/ul><p>\u00a0<\/p><p><b>Neuro-Oncology<\/b><\/p><ul><li><b>Video follow-ups:<\/b><span style=\"font-weight: 400\"> A randomized study showed that video follow-ups can effectively substitute for clinical follow-ups for patients with gliomas, which was a great boon during the COVID-19 pandemic.<\/span><\/li><li><b>Mebendazole in glioma:<\/b><span style=\"font-weight: 400\"> A phase 1 study was undertaken to repurpose the anti-parasitic medicine mebendazole for the treatment of glioblastoma.<\/span><\/li><li><b>Bevacizumab:<\/b><span style=\"font-weight: 400\"> Helped establish the role of generic and low-dose bevacizumab through publications.<\/span><\/li><li><b>Brain metastasis clinic:<\/b><span style=\"font-weight: 400\"> A multidisciplinary clinic started in April 2018 improved care by changing the treatment plan for nearly half of the patients with difficult brain metastasis cases.<\/span><\/li><\/ul><p>\u00a0<\/p><p><b>U<\/b><b>ro-Oncology<\/b><\/p><ul><li><span style=\"font-weight: 400\">Studied and established the role of Paclitaxel-Platinum as adjuvant and palliative therapy in Penile cancers.<\/span><\/li><li><span style=\"font-weight: 400\">Established the safety and efficacy of multiple therapies for Renal cell carcinoma and Prostate cancer.<\/span><\/li><\/ul><p>\u00a0<\/p><p><b>Gastrointestinal and Breast\/Gynecological Cancers<\/b><\/p><ul><li><span style=\"font-weight: 400\">Has established and studied multiple regimens in various settings for GI tumors.<\/span><\/li><li><span style=\"font-weight: 400\">Established internationally recognized protocols for treatment in Breast and Gynecological cancers while at Malabar Cancer center.<\/span><\/li><\/ul>                        <\/div>\n\n                    <\/div>\n\n                <\/div><!-- .elementskit-card END -->\n\n                \n                <div class=\"elementskit-card \">\n                    <div class=\"elementskit-card-header\" id=\"primaryHeading-2-34e2583\">\n                        <a href=\"#collapse-a81540169e0891c35504\" class=\"ekit-accordion--toggler elementskit-btn-link collapsed\" data-ekit-toggle=\"collapse\" data-target=\"#Collapse-a81540169e0891c35504\" aria-expanded=\"false\" aria-controls=\"Collapse-a81540169e0891c35504\">\n                            \n                            <span class=\"ekit-accordion-title\">Honors &amp; Awards<\/span>\n\n                            \n                                <div class=\"ekit_accordion_icon_group\">\n                                    <div class=\"ekit_accordion_normal_icon\">\n                                        <!-- Normal Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"icon icon-down-arrow1\"><\/i>                                    <\/div>\n\n                                    <div class=\"ekit_accordion_active_icon\">\n                                        <!-- Active Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"icon icon-up-arrow1\"><\/i>                                    <\/div>\n                                <\/div>\n\n                            \n                                                    <\/a>\n                    <\/div>\n\n                    <div id=\"Collapse-a81540169e0891c35504\" class=\" collapse\" aria-labelledby=\"primaryHeading-2-34e2583\" data-parent=\"#accordion-69e0891c35504\">\n\n                        <div class=\"elementskit-card-body ekit-accordion--content\">\n                            <p>Dr. (Prof.) Vijay Patil is a preeminent figure in oncology, celebrated for his innovative spirit and patient-centered philosophy. His groundbreaking work has been recognized with numerous national and international honors, solidifying his reputation as a leader in his field. He was awarded the prestigious Gold Medal in Medical Oncology at Tata Memorial Centre, an honor that recognizes not only his academic excellence but also his clinical innovation. Furthermore, he has been honored with the National Young Oncologist Award for his exemplary leadership in clinical research and mentorship. A frequent keynote speaker at major oncology conferences, Dr. Patil is widely respected for his ability to translate complex, cutting-edge science into tangible, real-world treatment solutions that benefit patients.<\/p><p><strong>Honors &amp; Awards<\/strong><\/p><p><strong>Professor in Medical Oncology (2022-till date, SunAct - Advanced Cancer Therapies)<\/strong>\u00a0<\/p><ul><li>ASCO Annual Conference, Oral Presentation (2024)<\/li><li>Centre of Excellence Award for Cell &amp; Gene Therapy (2024)<\/li><\/ul><p>\u00a0<\/p><p><strong>Professor in Medical Oncology (2020-2022, Tata Memorial Hospital, Mumbai)<\/strong><\/p><ul><li>ASCO annual conference Oral presentation 2020<\/li><li>ASCO annual conference Oral presentation 2022<\/li><li>ICON Oration 2022-ICON's Geeta Rameshchandra Gandhi Oration<\/li><li>SHRI VIJAY BATRA RESEARCH FOUNDATION (ADLEY GROUP) AWARD for the year 2022<\/li><\/ul><p>\u00a0<\/p><p><strong>Associate Professor in Medical Oncology (2017-December 2019, Tata Memorial Hospital, Mumbai)<\/strong><\/p><ul><li>ISNO best paper (poster) 2017<\/li><li>ISNO best paper (oral) 2018<\/li><li>ASCO annual conference Oral presentation 2018<\/li><li>ESMO Asia travel grant 2018<\/li><li>FHNO Best paper Award 2019<\/li><\/ul><p>\u00a0<\/p><p><strong>Assistant Professor in Medical Oncology (2015-December 2016, Tata Memorial Hospital, Mumbai)<\/strong><\/p><ul><li>ISMPO best paper- Kala Venkat award 2016<\/li><li>ESMO Asia travel grant 2016<\/li><\/ul><p>\u00a0<\/p><p><strong>A<\/strong><strong>ssistant Professor in Medical Oncology (2013-2014, Malabar Cancer Centre, Kerala, India)<\/strong><\/p><ul><li>ISO best paper award in ICC 2013<\/li><li>ICON best geriatric case award 2014<\/li><li>ASCO-IDEA AWARD 2014<\/li><li>Best of ASCO India award 2014<\/li><\/ul><p>\u00a0<\/p><p><strong>DM, Medical Oncology (2010-2013, TMH, Mumbai)<\/strong><\/p><ul><li>Gold medal for standing first in Medical oncology for the year 2013<\/li><li>Best poster award in ISO conference, Bhubaneswar 2011<\/li><li>Best paper (oral presentation) award in ISMPO conference Vizag 2012<\/li><li>ACORD Fellowship, Australia 2012<\/li><\/ul><p>\u00a0<\/p><p><strong>MD (2006-2009, PGIMER, Chandigarh)<\/strong><\/p><ul><li>Kataria Gold Medal for Best Post Graduate student of year 2009<\/li><li>Bruce Davis Gold Medal in Palliative Medicine 2007 (Bruce Davis Gold Medal in Palliative medicine is given to a junior doctor following a screening test and final exam conducted at National level by the Institute of Palliative Medicine, Kozhikode, Kerala)<\/li><\/ul><p>\u00a0<\/p><p><strong>MBBS (2000-2006, Seth GSMC &amp; KEMH, Mumbai)<\/strong><\/p><ul><li>Dr L H Hiranandani prize for highest marks in subject of ENT (OCT-2003)<\/li><li>Dr V G Rao 1st prize for highest marks in subject of P.S.M (OCT-2003)<\/li><li>Dr G W Kane Memorial prize for highest marks in subject of Surgery (OCT-2004)<\/li><li>Dr R H Karmarkar Gold medal for standing first in General Surgery (OCT-2004)<\/li><li>Dr N D Patel Medicine Prize for highest marks in subject of Medicine (OCT-2004)<\/li><li>H.Sir Jaswant Singhji Limbdi Prize for highest aggregate marks at 3rd MBBS (OCT-2004)<\/li><\/ul>                        <\/div>\n\n                    <\/div>\n\n                <\/div><!-- .elementskit-card END -->\n\n                \n                <div class=\"elementskit-card \">\n                    <div class=\"elementskit-card-header\" id=\"primaryHeading-3-34e2583\">\n                        <a href=\"#collapse-46e184f69e0891c35504\" class=\"ekit-accordion--toggler elementskit-btn-link collapsed\" data-ekit-toggle=\"collapse\" data-target=\"#Collapse-46e184f69e0891c35504\" aria-expanded=\"false\" aria-controls=\"Collapse-46e184f69e0891c35504\">\n                            \n                            <span class=\"ekit-accordion-title\">Research<\/span>\n\n                            \n                                <div class=\"ekit_accordion_icon_group\">\n                                    <div class=\"ekit_accordion_normal_icon\">\n                                        <!-- Normal Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"icon icon-down-arrow1\"><\/i>                                    <\/div>\n\n                                    <div class=\"ekit_accordion_active_icon\">\n                                        <!-- Active Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"icon icon-up-arrow1\"><\/i>                                    <\/div>\n                                <\/div>\n\n                            \n                                                    <\/a>\n                    <\/div>\n\n                    <div id=\"Collapse-46e184f69e0891c35504\" class=\" collapse\" aria-labelledby=\"primaryHeading-3-34e2583\" data-parent=\"#accordion-69e0891c35504\">\n\n                        <div class=\"elementskit-card-body ekit-accordion--content\">\n                            <p><strong>Head and Neck Cancer<\/strong><\/p><ol><li>Patil V, Noronha V, Dhumal SB, et al.<br \/><strong>Low-cost oral metronomic chemotherapy versus intravenous cisplatin<\/strong> in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, <strong>non-inferiority, randomised, phase 3 trial<\/strong>.\u00a0<\/li><li>Patil VM, Noronha V, Joshi A, et al.<br \/><strong>Phase I\/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory\/Early-Failure Oral Cancer<\/strong>.<\/li><li>Patil VM, Noronha V, Joshi A, et al. A prospective<br \/><strong>randomized phase II study comparing metronomic chemotherapy with chemotherapy<\/strong> (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.<\/li><li>Joshi A, Patil VM, Noronha V, et al.<br \/><strong>Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel<\/strong> as second-line or above therapy in recurrent head and neck cancer.<\/li><li>Noronha V, Patil VM, Joshi A, al.<br \/><strong>Nimotuzumab-cisplatin-radiation versus cisplatin-radiation<\/strong> in HPV negative oropharyngeal cancer.<\/li><li>Patil VM, Noronha V, Joshi A, et al. A<br \/><strong>randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy<\/strong> alone in locally advanced head and neck cancer.<\/li><li>Noronha V, Joshi A, Patil VM, et al.<br \/><strong>Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial<\/strong>.<\/li><li>Patil VM, Joshi A, Noronha V, et al.<br \/><strong>Technically unresectable recurrent oral cancers: Is NACT the answer?<\/strong><\/li><li>Patil VM, Noronha V, Joshi A, et al.<br \/><strong>Neoadjuvant chemotherapy in geriatric head and neck cancers<\/strong>.<\/li><li>Patil VM, Chougule A, Noronha V, et al.<br \/><strong>DPYD Mutation in Indian Patients<\/strong>.<\/li><li>Patil VM, Noronha V, Thiagarajan S, et al.<br \/><strong>Salvage surgery in head and neck cancer: Does it improve outcomes?<\/strong><\/li><li>Patil VM, Joshi A, Noronha V, et al.<br \/><strong>Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors<\/strong> (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation).<\/li><li>Patil VM, Prabhash K, Noronha V, et al.<br \/><strong>Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers<\/strong>.<\/li><\/ol><p>\u00a0<\/p><p><strong>Thoracic Tumors<\/strong><\/p><ol><li>Patil VM, Noronha V, Joshi A, et al.<br \/><strong>Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma<\/strong>.<\/li><li>Noronha V, Patil VM, Joshi A, et al.<br \/><strong>Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer<\/strong>.<\/li><li>Patil V, Noronha V, Joshi A, et al.<br \/><strong>Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine<\/strong> With Platinum in Advanced Squamous Lung Cancer.<\/li><li>Patil V, Joshi A, Noronha V, et al,<br \/><strong>Randomized phase 3 open label study of quality of life<\/strong> of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer.<\/li><li>Noronha V, Ramaswamy A. Patil VM, et al.<br \/><strong>ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country<\/strong>.<\/li><li>Joshi A, Pande N, Noronha V, et al.<br \/><strong>ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes<\/strong>.<\/li><li>Joshi AP, Chandrakanth MV, Noronha V, et al.<br \/><strong>Ceritinib in anaplastic lymphoma kinase-positive nonsmall cell lung cancer<\/strong> among patients who were previously exposed to crizotinib: Experience from the Indian subcontinent.<\/li><li>Noronha V, Talreja VT, Patil V, et al.<br \/><strong>Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience<\/strong>.<\/li><li>Kate S, Chougule A, Joshi A, et al.<br \/><strong>Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis<\/strong>.<\/li><li>Noronha V, Choughule A, Patil VM, et al.<br \/><strong>Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment<\/strong>.<\/li><\/ol><p>\u00a0<\/p><p><strong>Neuro-Oncology<\/strong><\/p><ol><li>Noronha V, Patil V, Ostwal V, et al.<br \/><strong>Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer<\/strong>.<\/li><li>Patil VM, Noronha V. Joshi A, et al.<br \/><strong>Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?<\/strong><\/li><li>Noronha V, Abraham G, Patil V, et al.<br \/><strong>A real-world data of Immune checkpoint inhibitors in solid tumors from India<\/strong>.<\/li><li>Ramaswamy A, Joshi A, Noronha V, et al.<br \/><strong>Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma<\/strong>- Results From a Tertiary Cancer Center in India.<\/li><li>Joshi A, Ramaswamy A, Noronha V, et al.<br \/><strong>Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria<\/strong>.<\/li><li>Zanwar S, Joshi A, Noronha V, et al.<br \/><strong>Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis<\/strong>.<\/li><li>Joshi A, Agarwala V, Ramaswamy A, et al.<br \/><strong>Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data<\/strong>.<\/li><li>Krishna VM, Noronha V, Prabhash K, et al.<br \/><strong>Sunitinib in metastatic renal cell carcimoma: a single-center experience<\/strong>.<\/li><li>Ramaswamy A, Joshi A, Noronha V, et al.<br \/><strong>Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center<\/strong>.<\/li><li>Agarwala V, Ramaswamy A, Joshi A, et al.<br \/><strong>Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis<\/strong>.<\/li><li>Noronha V, Joshi A, Muddu VK, et al.<br \/><strong>Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre<\/strong>.<\/li><\/ol><p>\u00a0<\/p><p><strong>Uro-Oncology<\/strong><\/p><ol><li>Noronha V, Patil V, Ostwal V, et al.<br \/><strong>Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer<\/strong>.<\/li><li>Patil VM, Noronha V, Joshi A, et al.<br \/><strong>Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?<\/strong><\/li><li>Noronha V, Abraham G, Patil V, et al.<br \/><strong>A real-world data of Immune checkpoint inhibitors in solid tumors from India<\/strong>.<\/li><li>Ramaswamy A, Joshi A, Noronha V, et al.<br \/><strong>Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma<\/strong>- Results From a Tertiary Cancer Center in India.<\/li><li>Joshi A, Ramaswamy A, Noronha V, et al.<br \/><strong>Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria<\/strong>.<\/li><li>Zanwar S, Joshi A, Noronha V, et al.<br \/><strong>Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis<\/strong>.<\/li><li>Joshi A, Agarwala V, Ramaswamy A, et al.<br \/><strong>Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data<\/strong>.<\/li><li>Krishna VM, Noronha V, Prabhash K, et al.<br \/><strong>Sunitinib in metastatic renal cell carcimoma: a single-center experience<\/strong>.<\/li><li>Ramaswamy A. Joshi A, Noronha V, et al.<br \/><strong>Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center<\/strong>.<\/li><li>Agarwala V, Ramaswamy A, Joshi A, et al.<br \/><strong>Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis<\/strong>.<\/li><li>Noronha V, Joshi A, Muddu VK, et al. <strong>Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre<\/strong>.<\/li><\/ol><p>\u00a0<\/p><p><strong>Gyn-Oncology<\/strong><\/p><ol><li>Dessai SB, Chakraborty S, Babu T, et al.<br \/><strong>Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients<\/strong> who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.<\/li><li>Chakraborty S, Geetha M, Dessai S, Patil VM.<br \/><strong>How well do elderly patients with cervical cancer tolerate definitive radiochemotherapy using RapidArc?<\/strong> Results from an institutional audit comparing elderly versus younger patients.<\/li><li>Dessai SB, Balasubramanian S, Patil VM, et al.<br \/><strong>Pelvic exenteration: experience from a rural cancer center in developing world<\/strong>.<\/li><\/ol><p>\u00a0<\/p><p><strong>Breast cancer<\/strong><\/p><ol><li>Bajpai J, Susan D, Patil V, et al.<br \/>\u00a0<strong>Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India<\/strong>.<\/li><\/ol><p>\u00a0<\/p><p><strong>Supportive Care<\/strong><\/p><ol><li>Patil V, Singhai P, Noronha V, et al.<br \/><strong>Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial<\/strong>.<\/li><li>Patil VM, Chakraborty S, Bhattacharjee A, Dessai S.<br \/><strong>Survey of the State of Implementation of the American Society of Clinical Oncology\/Oncology Nursing Society Safety Standards for Chemotherapy Administration in India<\/strong>.<\/li><li>Patil V, Noronha V, Joshi A, et al.<br \/><strong>Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline<\/strong>.<\/li><li>Patil VM, Noronha V. Joshi A, et al.<br \/><strong>Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India<\/strong>.<\/li><li>Patil V, Noronha V, Joshi A, et al.<br \/><strong>Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach<\/strong>.<\/li><li>Dessai SB, Chakraborty S, Sajeev Kumar PB, et al.<br \/><strong>Pilot study of single-day distress screening with the NCCN distress thermometer to evaluate the feasibility of routine distress screening in tertiary cancer center in rural India.<\/strong><\/li><li>Joshi A, Patil VM, Noronha V, et al.<br \/><strong>EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden<\/strong>.<\/li><\/ol>                        <\/div>\n\n                    <\/div>\n\n                <\/div><!-- .elementskit-card END -->\n\n                \n                <div class=\"elementskit-card \">\n                    <div class=\"elementskit-card-header\" id=\"primaryHeading-4-34e2583\">\n                        <a href=\"#collapse-61b379369e0891c35504\" class=\"ekit-accordion--toggler elementskit-btn-link collapsed\" data-ekit-toggle=\"collapse\" data-target=\"#Collapse-61b379369e0891c35504\" aria-expanded=\"false\" aria-controls=\"Collapse-61b379369e0891c35504\">\n                            \n                            <span class=\"ekit-accordion-title\">Publications<\/span>\n\n                            \n                                <div class=\"ekit_accordion_icon_group\">\n                                    <div class=\"ekit_accordion_normal_icon\">\n                                        <!-- Normal Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"icon icon-down-arrow1\"><\/i>                                    <\/div>\n\n                                    <div class=\"ekit_accordion_active_icon\">\n                                        <!-- Active Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"icon icon-up-arrow1\"><\/i>                                    <\/div>\n                                <\/div>\n\n                            \n                                                    <\/a>\n                    <\/div>\n\n                    <div id=\"Collapse-61b379369e0891c35504\" class=\" collapse\" aria-labelledby=\"primaryHeading-4-34e2583\" data-parent=\"#accordion-69e0891c35504\">\n\n                        <div class=\"elementskit-card-body ekit-accordion--content\">\n                            <p>\t\t<div data-elementor-type=\"section\" data-elementor-id=\"4555\" class=\"elementor elementor-4555\" data-elementor-post-type=\"elementor_library\">\n\t\t\t<div class=\"elementor-element elementor-element-3d462406 e-flex e-con-boxed e-con e-parent\" data-id=\"3d462406\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4a33fde2 elementor-widget__width-auto elementor-widget elementor-widget-n-accordion\" data-id=\"4a33fde2\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1240\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1240\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Head &amp; Neck <\/div><\/span>\n\t\t\t\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1240\" class=\"elementor-element elementor-element-961d8f1 e-con-full e-flex e-con e-child\" data-id=\"961d8f1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-19d0f33f elementor-widget__width-inherit elementor-widget-tablet__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"19d0f33f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong><span class=\"price click-to-show\" data-show=\"accordion_hn\">Head &amp; Neck<\/span><\/strong><\/p><ol><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/394093298_Long-term_outcomes_of_consecutive_patients_of_oropharyngeal_cancer_treated_with_radical_radiotherapy\">Long-term outcomes of consecutive patients of oropharyngeal cancer treated with radical radiotherapy<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/394066444_Nutritional_status_and_impact_on_outcomes_of_patients_with_locally_advanced_head_and_neck_squamous_cell_carcinoma_treated_with_concurrent_chemoradiotherapy_a_pre-planned_secondary_analysis_of_a_phase_\"> Nutritional status and impact on outcomes of patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: a pre-planned secondary analysis of a phase 3 randomized controlled trial<\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.researchgate.net\/publication\/363658315_Long_term_outcomes_of_a_randomized_controlled_clinical_trial_comparing_the_efficacy_of_Cabazitaxel_versus_docetaxel_as_second-line_or_above_therapy_in_recurrent_head_and_neck_cancer\"><span style=\"font-weight: 400;\"><span style=\"color: #3366ff;\">Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.\u00a0<\/span><\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/364593756_Low-Dose_Immunotherapy_in_Head_and_Neck_Cancer_A_Randomized_Study\"><span style=\"font-weight: 400;\">Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361949797_Proposed_sub-_compartmentalisation_of_high_infratemporal_fossa_involvement_in_gingivobuccal_cancers_and_its_impact_on_clinical_outcome_and_AJCC_8th_edition_A_narrative_review\"><span style=\"font-weight: 400;\">Proposed sub- compartmentalisation of high infratemporal fossa involvement in gingivobuccal cancers and its impact on clinical outcome and AJCC 8th edition. A narrative review.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/360907005_Long_term_toxicity_and_tolerance_of_concurrent_docetaxel_with_radiotherapy_in_cisplatin-ineligible_head_and_neck_cancer_patients\"><span style=\"font-weight: 400;\">Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361820236_Anaplastic_Cancer_Our_Experience\"><span style=\"font-weight: 400;\">Anaplastic Cancer: Our Experience.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361380805_Change_in_Pattern_of_Failure_in_Head_and_Neck_Cancer\"><span style=\"font-weight: 400;\">Change in Pattern of Failure in Head and Neck Cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361202545_Non-surgical_Organ_preservation_in_Laryngeal_and_Hypopharyngeal_Cancers_An_audit_from_the_clinic\"><span style=\"font-weight: 400;\">Non-surgical Organ preservation in Laryngeal and Hypopharyngeal Cancers: An audit from the clinic.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/360997436_Prognostic_value_of_radiological_extranodal_extension_rENE_detected_by_computed_tomography_CT_for_predicting_outcomes_in_locally_advanced_head_and_neck_squamous_cell_cancer_LAHNSCC_patients_treated_wi\"><span style=\"font-weight: 400;\">Prognostic value of radiological extranodal extension (rENE) detected by computed tomography (CT) for predicting outcomes in locally advanced head and neck squamous cell cancer (LAHNSCC) patients treated with radical concurrent chemoradiotherapy (CCRT).\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361124942_Real-world_data_of_use_of_nivolumab_in_platinum_refractory_head_and_neck_cancers\"><span style=\"font-weight: 400;\">Real-world data of use of nivolumab in platinum refractory head and neck cancers.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361125660_Real_world_evidence_for_use_of_NACT_in_locally_advanced_external_auditory_canal_cancer\"><span style=\"font-weight: 400;\">Real world evidence for use of NACT in locally advanced external auditory canal cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361132701_Real_world_data_of_neoadjuvant_and_adjuvant_chemotherapy_in_head_neck_osteosarcoma_Experience_from_a_tertiary_care_center_in_India\"><span style=\"font-weight: 400;\">Real world data of neoadjuvant and adjuvant chemotherapy in head neck osteosarcoma: Experience from a tertiary care center in India.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361133747_Metronomic_systemic_PCm_paclitaxel_carboplatin_metronomic_neoadjuvant_chemotherapy_in_head_and_neck_cancer\"><span style=\"font-weight: 400;\">Metronomic systemic PCm (paclitaxel, carboplatin + metronomic) neoadjuvant chemotherapy in head and neck cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361976094_A_retrospective_analysis_of_patients_administered_neoadjuvant_chemotherapy_NACT_with_paclitaxel_plus_carboplatin_with_oral_metronomic_chemotherapy_OMCT_in_locally_advanced_borderline_resectabletechnic\"><span style=\"font-weight: 400;\">A retrospective analysis of patients administered neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin with oral metronomic chemotherapy (OMCT) in locally advanced borderline resectable\/technically unresectable head and neck cancers.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/362969991_Phase_III_randomized_control_study_evaluating_adjuvant_metronomic_chemotherapy_in_locally_advanced_head_and_neck_cancers_post-radical_chemoradiation_MACE-CTRT\"><span style=\"font-weight: 400;\">Phase III randomized control study evaluating adjuvant metronomic chemotherapy in locally advanced head and neck cancers post-radical chemoradiation (MACE-CTRT).\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400; color: #3366ff;\">1-s2.0-S1368837522001051-main<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/360983365_PO-1094_Long_term_outcomes_of_630_consecutive_patients_of_oropharyngeal_cancer_treated_with_radiotherapy\"><span style=\"font-weight: 400;\">PO-1094 Long term outcomes of 630 consecutive patients of oropharyngeal cancer treated with radiotherapy.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/359351248_Safety_and_efficacy_of_pembrolizumab_with_chemotherapy_in_locally_advanced_head_and_neck_cancers\"><span style=\"font-weight: 400;\">Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/359007703_Atypical_posterior_reversible_encephalopathy_syndrome_associated_with_Lenvatinib_therapy_in_a_patient_with_metastatic_thyroid_cancer-A_case_report\"><span style=\"font-weight: 400;\">Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer\u2014A case report.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/359521425_Quality_of_life_in_patients_with_locally_advanced_head_and_neck_squamous_cell_carcinoma_undergoing_concurrent_chemoradiation_with_once-a-week_versus_once-every-3-_weeks_cisplatin\"><span style=\"font-weight: 400;\">Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3- weeks cisplatin.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/358488797_Prognostic_and_predictive_roles_of_cancer_stem_cell_markers_in_head_and_neck_squamous_cell_carcinoma_patients_receiving_chemoradiotherapy_with_or_without_nimotuzumab\"><span style=\"font-weight: 400;\">Prognostic and predictive roles of cancer stem cell markers in head and neck squamous cell carcinoma patients receiving chemoradiotherapy with or without nimotuzumab.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/357541655_Hypomagnesemia_in_patients_with_locally_advanced_head_and_neck_cancer_treated_weekly_cisplatin-incidence_and_impact_on_outcomes\"><span style=\"font-weight: 400;\">Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/357418538_Post_hoc_analysis_of_the_screening_log_of_phase_III_investigator-initiated_randomized_clinical_trial_comparing_palliative_oral_metronomic_versus_intravenous_chemotherapy_in_head-and-neck_cancer\"><span style=\"font-weight: 400;\">Post hoc analysis of the screening log of phase III investigator\u2011initiated randomized clinical trial comparing palliative oral metronomic versus intravenous chemotherapy in head\u2011and\u2011neck cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/356822172_Prospective_Phase_II_Open-Label_Randomized_Controlled_Trial_to_Compare_Mandibular_Preservation_in_Upfront_Surgery_With_Neoadjuvant_Chemotherapy_Followed_by_Surgery_in_Operable_Oral_Cavity_Cancer\"><span style=\"font-weight: 400;\">Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/356738280_Efficacy_and_safety_of_neoadjuvant_chemotherapy_NACT_with_paclitaxel_plus_carboplatin_and_oral_metronomic_chemotherapy_OMCT_in_patients_with_technically_unresectable_oral_squamous_cell_carcinoma_OSCC\"><span style=\"font-weight: 400;\">Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC).\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400; color: #3366ff;\">Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation \u2013 a phase 3 study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/349180551_Concurrent_chemoradiotherapy_for_locally_advanced_unresectable_adenoid_cystic_carcinoma_of_head_and_neck_experience_from_a_single_institute\"><span style=\"font-weight: 400;\">Concurrent chemoradiotherapy for locally advanced unresectable adenoid cystic carcinoma of head and neck: experience from a single institute.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/355747928_Audit_of_Demographics_Treatment_Patterns_and_Outcomes_of_Differentiated_Thyroid_Cancers_Treated_with_Tyrosine_Kinase_Inhibitors\"><span style=\"font-weight: 400;\">Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/354820359_Weight_loss_and_its_impact_on_outcome_in_head_and_cancer_patients_during_chemo-radiation\"><span style=\"font-weight: 400;\">Weight loss and its impact on outcome in head and cancer patients during chemo-radiation.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/335707265_Delirium_and_seizures_in_a_patient_with_head-and-neck_squamous_cell_carcinoma_on_docetaxel_cisplatin_and_5-fluorouracil\"><span style=\"font-weight: 400;\">Delirium and seizures in a patient with head-and-neck squamous cell carcinoma on docetaxel, cisplatin, and 5-fluorouracil.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The efficacy of low-dose immunotherapy in head-and-neck cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Adding to the debate on once-a-week versus once-every-3-weeks cisplatin dosing in concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Influence of Hypothyroidism After Chemoradiation on Outcomes in Head and Neck Cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin ineligible head and neck cancer patients.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.researchgate.net\/publication\/354849024_Quality_of_life_in_patients_with_locally_advanced_head_and_neck_cancer_treated_with_concurrent_chemoradiation_with_cisplatin_and_nimotuzumab_versus_cisplatin_alone_-_Additional_data_from_a_phase_3_tri\"><span style=\"font-weight: 400;\"><span style=\"color: #3366ff;\">Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone &#8211; Additional data from a phase 3 trial.\u00a0<\/span><\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/354469578_Aspiration_pneumonia_in_head_and_neck_cancer_patients_undergoing_concurrent_chemoradiation_from_India_Findings_from_a_post_hoc_analysis_of_a_phase_3_study\"><span style=\"font-weight: 400;\">Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/354747455_910P_Repurposing_pantoprazole_in_advanced_head_and_neck_squamous_cell_carcinoma_A_phase_III_randomized_study\"><span style=\"font-weight: 400;\">910P Repurposing pantoprazole in advanced head and neck squamous cell carcinoma: A phase I\/II randomized study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/354751637_865MO_RMAC_study_A_randomized_study_evaluating_the_efficacy_of_metronomic_adjuvant_chemotherapy_in_patients_with_recurrent_head_and_neck_cancers_post_salvage_surgery_not_eligible_for_re-irradiation\"><span style=\"font-weight: 400;\">865MO RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/353917056_An_Audit_of_Systemic_Therapy_in_Medullary_Carcinoma_Thyroid\"><span style=\"font-weight: 400;\">An Audit of Systemic Therapy in Medullary Carcinoma Thyroid.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/353999681_Systemic_Therapy_in_Thyroid_Cancer\"><span style=\"font-weight: 400;\">Systemic Therapy in Thyroid Cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/352869273_Advances_in_pharmacotherapy_for_head_and_neck_cancer\"><span style=\"font-weight: 400;\">Advances in pharmacotherapy for head and neck cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/351785072_Post_hoc_analysis_of_a_randomized_controlled_trial_comparing_concurrent_chemoradiation_with_cisplatin_versus_nimotuzumab-cisplatin_focusing_on_acute_oral_mucositis\"><span style=\"font-weight: 400;\">Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/352072573_Outcome_of_neoadjuvant_chemotherapy_NACT_with_paclitaxel_plus_carboplatin_and_oral_metronomic_chemotherapy_OMCT_in_patients_with_technically_unresectable_oral_cavity_squamous_cell_carcinoma_SCC\"><span style=\"font-weight: 400;\">Outcome of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC).\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/350400873_Aprepitant_for_patients_with_head-and-neck_cancer_receiving_once-a-week_cisplatin_with_radiation_Is_it_required\"><span style=\"font-weight: 400;\">Aprepitant for patients with head-and-neck cancer receiving once-a-week cisplatin with radiation: Is it required?.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/349958172_Correlation_of_transcriptionally_active_human_papillomavirus_status_with_the_clinical_and_molecular_profiles_of_head_and_neck_squamous_cell_carcinomas\"><span style=\"font-weight: 400;\">Correlation of transcriptionally active human papillomavirus status with the clinical and molecular profiles of head and neck squamous cell carcinomas.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/349918666_Intensity-modulated_radiation_therapy_for_nasal_cavity_and_paranasal_sinus_tumors_Experience_from_a_single_institute\"><span style=\"font-weight: 400;\">Intensity\u2010modulated radiation therapy for nasal cavity and paranasal sinus tumors: Experience from a single institute.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/348912384_The_Pattern_of_Care_of_Use_of_Nivolumab_in_Head_and_Neck_Cancers_-_Audit_From_a_Tertiary_Cancer_Centre\"><span style=\"font-weight: 400;\">The Pattern of Care of Use of Nivolumab in Head and Neck Cancers \u2013 Audit From a Tertiary Cancer Centre.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/347889661_Oral_metronomic_therapy_in_head_and_neck_cancer_-_Authors'_reply\"><span style=\"font-weight: 400;\">Oral metronomic therapy in head and neck cancer \u2013 Authors&#8217; reply.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/357567070_FGFR_alterations_in_head-and-neck_cancer\"><span style=\"font-weight: 400;\">FGFR alterations in head-and-neck cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/346271250_SAFETY_AND_EFFICACY_OF_CONCURRENT_CHEMORADIOTHERAPY_FOR_HEAD-AND-NECK_CANCERS_IN_OLDER_VERSUS_YOUNGER_PATIENTS_POST_HOC_ANALYSIS_OF_A_RANDOMISED_CONTROLLED_TRIAL\"><span style=\"font-weight: 400;\">SAFETY AND EFFICACY OF CONCURRENT CHEMORADIOTHERAPY FOR HEAD-AND-NECK CANCERS IN OLDER VERSUS YOUNGER PATIENTS: POST HOC ANALYSIS OF A RANDOMISED CONTROLLED TRIAL.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/352359984_Chemoradiation_in_Unresectable_Oral_Cavity_Cancer_A_Myth_or_Reality\"><span style=\"font-weight: 400;\">Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/344311982_Safety_and_efficacy_of_concurrent_chemoradiotherapy_for_head-and-neck_cancers_in_older_versus_younger_patients_Post_hoc_analysis_of_a_randomized_controlled_trial\"><span style=\"font-weight: 400;\">Safety and efficacy of concurrent chemoradiotherapy for head-and-neck cancers in older versus younger patients: Post hoc analysis of a randomized controlled trial.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/344303190_Prognostic_and_predictive_significance_of_nuclear_HIF1a_expression_in_locally_advanced_HNSCC_patients_treated_with_chemoradiation_with_or_without_nimotuzumab\"><span style=\"font-weight: 400;\">Prognostic and predictive significance of nuclear HIF1\u03b1 expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/344477580_Molecular_tumor_board_Case_4_Salivary_Gland_Cancer_Novel_therapeutic_options_as_a_result_of_comprehensive_molecular_profiling\"><span style=\"font-weight: 400;\">Molecular tumor board: Case 4 Salivary Gland Cancer: Novel therapeutic options as a result of comprehensive molecular profiling.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/343758851_Low-cost_oral_metronomic_chemotherapy_versus_intravenous_cisplatin_in_patients_with_recurrent_metastatic_inoperable_head_and_neck_carcinoma_an_open-label_parallel-group_non-inferiority_randomised_phas\"><span style=\"font-weight: 400;\">Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/343760075_Articles_Low-cost_oral_metronomic_chemotherapy_versus_intravenous_cisplatin_in_patients_with_recurrent_metastatic_inoperable_head_and_neck_carcinoma_an_open-label_parallel-_group_non-inferiority_rando\"><span style=\"font-weight: 400;\">Articles Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel- group, non-inferiority, randomised, phase 3 trial.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/342305326_Long-term_outcomes_of_locally_advanced_and_borderline_resectable_esthesioneuroblastoma_and_sinonasal_tumor_with_neuroendocrine_differentiation_treated_with_neoadjuvant_chemotherapy\"><span style=\"font-weight: 400;\">Long\u2011term outcomes of locally advanced and borderline resectable esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation treated with neoadjuvant chemotherapy.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/340474531_Beyond_conventional_chemotherapy_targeted_therapy_and_immunotherapy_in_squamous_cell_cancer_of_the_oral_cavity\"><span style=\"font-weight: 400;\">Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341915914_Incidence_and_Outcome_of_Second_Malignancy_in_Primary_Treated_Head_and_Neck_Cancer\"><span style=\"font-weight: 400;\">Incidence and Outcome of Second Malignancy in Primary Treated Head and Neck Cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341764142_Salvage_surgery_in_head_and_neck_cancer_Does_it_improve_outcomes\"><span style=\"font-weight: 400;\">Salvage surgery in head and neck cancer: Does it improve outcomes?.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341628073_Indication_of_adjuvant_chemoradiation_post_neoadjuvant_chemotherapy_in_very_locally_advanced_borderline_resectable_head_and_neck_cancer\"><span style=\"font-weight: 400;\">Indication of adjuvant chemoradiation post neoadjuvant chemotherapy in very locally advanced borderline resectable head and neck cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341628771_Optimal_cumulative_cisplatin_dose_for_radio-sensitization_in_locally_advanced_head_and_neck_cancer\"><span style=\"font-weight: 400;\">Optimal cumulative cisplatin dose for radio-sensitization in locally advanced head and neck cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341628779_Hypothyroidism_and_its_impact_on_outcomes_in_head_and_neck_cancer\"><span style=\"font-weight: 400;\">Hypothyroidism and its impact on outcomes in head and neck cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341629316_A_phase_III_randomized_clinical_trial_of_diclofenac_versus_tramadol_for_mucositis-related_pain_in_head_and_neck_cancer_patients_undergoing_concurrent_chemoradiation\"><span style=\"font-weight: 400;\">A phase III randomized clinical trial of diclofenac versus tramadol for mucositis-related pain in head and neck cancer patients undergoing concurrent chemoradiation.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341629665_Incidence_of_5-fluorouracil_related_in_cardiotoxicity_in_patients_with_head_and_neck_cancer\"><span style=\"font-weight: 400;\">Incidence of 5-fluorouracil related in cardiotoxicity in patients with head and neck cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341632922_Second_malignancy_post-chemoradiation_in_head_and_neck_cancer_patients\"><span style=\"font-weight: 400;\">Second malignancy post-chemoradiation in head and neck cancer patients.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Evolving role of immunotherapy in head-and-neck cancers: A systemic review.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Current and Emerging Role of Chemotherapy in Oral Cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">343PQTWiST analysis to compare the benefit of Metronomic chemotherapy versus intravenous cisplatin for patients with Head and neck cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">337OQuality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of Cabazitaxel versus docetaxel in recurrent Head and Neck Cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">342PQOL analysis of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second line or above therapy in recurrent head and neck cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Results of a phase II randomized controlled clinical trial comparing e\ufb03cacyof Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">1098PIncidence and impact of DPD mutation on neoadjuvant chemotherapy in head and neck cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Carboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neoadjuvant chemotherapy in geriatric head and neck cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Role of neoadjuvant chemotherapy in advanced carcinoma of the hypopharynx and larynxLetter to the Editor.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Expectations and preferences for palliative chemotherapy in head and neck cancers patients.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">386P Expectations and preferences for palliative chemotherapy in head and neck cancers patients.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Toxicity analysis of docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy in Indian patients with head and neck cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Preoperative Chemotherapy and Metronomic Scheduling of Chemotherapy in Locally Advanced Oral Cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Toxicity, tolerance and outcomes of carboplatin based CTRT ( concurrent chemoradiation) in head and neck cancers in patients who were not fit for cisplatin based CTRT.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Time-Dependent Area under the ROC Curve for Optimum Biological Dose Detection.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent\/metastatic head and neck cancers patients.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Metronomic palliative chemotherapy in maxillary sinus tumor.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Efficacy of second\u2011line erlotinib in patients postprogression of first\u2011line chemotherapy in head and neck cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Technically unresectable recurrent oral cancers: Is NACT the answer?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Head and neck cancer in geriatric patients: Analysis of the pattern of care given at a tertiary cancer care center.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cisplatin based adjuvant chemoradiation following neoadjuvant chemotherapy and surgery in advanced oral cavity cancers: A deliverable regimen?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Molecular biology of head and neck cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Chemoprevention in head and neck cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Extra-lymphatic filariasis at reconstructive surgery flap site recurrence of head and neck cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neoadjuvant chemotherapy and surgical margin in technically unresectable buccal mucosa cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neoadjuvant chemotherapy in advanced sinonasal teratocarcinosarcoma with intracranial extension: Report of two cases with literature review.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Does the use of induction chemotherapy in oral cavity cancer compromise subsequent loco-regional treatment delivery: Results from a matched pair analysis.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neoadjuvant Chemotherapy in Technically Unresectable Oral Cancers: Does Human Papillomavirus Make a Difference?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Metronomic chemotherapy in platinum-insensitive failures and\/or early failures postmultimodality management in oral cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">NACT in locally advanced oral cancers : Does HPV make a difference?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Compliance to NACT in T4 oral cancers :The place, person, socioeconomic status or assistance.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.researchgate.net\/publication\/341632952_Effect_of_early_integration_of_specialized_palliative_care_into_standard_oncologic_treatment_on_the_quality_of_life_of_patients_with_advanced_head_and_neck_cancers_A_phase_III_randomized_controlled_tr\"><span style=\"font-weight: 400;\"><span style=\"color: #3366ff;\">Effect of early integration of specialized palliative care into standard oncologic treatment on the quality of life of patients with advanced head and neck cancers: A phase III randomized controlled trial.\u00a0<\/span><\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341633036_Quality_of_life_in_patients_with_locally_advanced_head_and_neck_cancer_undergoing_chemoradiation_with_once-a-week_versus_once-every-three-weeks_cisplatin\"><span style=\"font-weight: 400;\">Quality of life in patients with locally advanced head and neck cancer undergoing chemoradiation with once-a-week versus once-every-three-weeks cisplatin.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341634593_Low-cost_oral_metronomic_versus_intravenous_chemotherapy_in_recurrent_inoperable_and_metastatic_head_and_neck_cancer_Phase_III_Metro-CIS_study\"><span style=\"font-weight: 400;\">Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase III Metro-CIS study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341634742_Prognostic_value_of_radiological_extranodal_extension_detected_by_computed_tomography_for_predicting_outcomes_in_head_and_neck_squamous_cell_cancer_patients_treated_with_radical_chemoradiotherapy\"><span style=\"font-weight: 400;\">Prognostic value of radiological extranodal extension detected by computed tomography for predicting outcomes in head and neck squamous cell cancer patients treated with radical chemoradiotherapy.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341636392_A_prospective_phase_II_open-label_randomized_controlled_trial_to_compare_mandibular_preservation_in_upfront_surgery_to_neoadjuvant_chemotherapy_followed_by_surgery_in_operable_oral_cavity_cancer\"><span style=\"font-weight: 400;\">A prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery to neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341637151_Aprepitant_in_weekly_cisplatin_with_radiation_in_head_and_neck_cancer_Is_it_required\"><span style=\"font-weight: 400;\">Aprepitant in weekly cisplatin with radiation in head and neck cancer: Is it required?.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341455000_Efficacy_and_safety_of_neoadjuvant_chemotherapy_NACT_with_paclitaxel_plus_carboplatin_and_oral_metronomic_chemotherapy_OMCT_in_patients_with_technically_unresectable_oral_cavity_squamous_cell_carcinom\"><span style=\"font-weight: 400;\">Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC).\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/340731245_Should_we_wait_or_not_The_preferable_option_for_patients_with_stage_IV_oral_cancer_in_COVID-19_pandemic\"><span style=\"font-weight: 400;\">Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/340418889_Clinical_outcomes_for_nasopharyngeal_cancer_with_intracranial_extension_after_taxane-based_induction_chemotherapy_and_concurrent_chemo-radiotherapy_in_the_modern_era\"><span style=\"font-weight: 400;\">Clinical outcomes for nasopharyngeal cancer with intracranial extension after taxane-based induction chemotherapy and concurrent chemo-radiotherapy in the modern era.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/339403417_Indian_clinical_practice_guideline_for_the_management_of_hypopharyngeal_carcinoma_A_consensus_statement\"><span style=\"font-weight: 400;\">Indian clinical practice guideline for the management of hypopharyngeal carcinoma: A consensus statement.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/339405829_Indian_clinical_practice_guideline_for_the_management_of_nasopharyngeal_carcinoma_A_consensus_statement\"><span style=\"font-weight: 400;\">Indian clinical practice guideline for the management of nasopharyngeal carcinoma: A consensus statement.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/339405885_Indian_clinical_practice_guideline_for_the_management_of_squamous_cell_carcinoma_of_head_and_neck_A_consensus_statement\"><span style=\"font-weight: 400;\">Indian clinical practice guideline for the management of squamous cell carcinoma of head and neck: A consensus statement.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/339408993_Indian_clinical_practice_guideline_for_the_management_of_oral_cavity_cancer_A_consensus_statement\"><span style=\"font-weight: 400;\">Indian clinical practice guideline for the management of oral cavity cancer: A consensus statement.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/339409055_Indian_clinical_practice_guideline_for_the_management_of_oropharyngeal_carcinoma_A_consensus_statement\"><span style=\"font-weight: 400;\">Indian clinical practice guideline for the management of oropharyngeal carcinoma: A consensus statement.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/339412484_Indian_clinical_practice_guideline_for_the_management_of_laryngeal_carcinoma_A_consensus_statement\"><span style=\"font-weight: 400;\">Indian clinical practice guideline for the management of laryngeal carcinoma: A consensus statement.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/338872307_Nimotuzumab-cisplatin-radiation_versus_cisplatin-radiation_in_HPV_negative_oropharyngeal_cancer\"><span style=\"font-weight: 400;\">Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/338387932_Palliative_chemotherapy_in_head_and_neck_cancer_balancing_between_beneficial_and_adverse_effects\"><span style=\"font-weight: 400;\">Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/343004756_The_pattern_of_care_in_head-and-neck_cancer_Comparison_between_before_and_during_the_COVID-19_pandemic\"><span style=\"font-weight: 400;\">The pattern of care in head-and-neck cancer: Comparison between before and during the COVID-19 pandemic.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/346318023_Effect_of_Early_Palliative_Care_on_the_Quality_of_Life_of_Patients_with_Advanced_Head_and_Neck_Cancers_A_Phase_3_Randomized_Controlled_Trial\"><span style=\"font-weight: 400;\">Effect of Early Palliative Care on the Quality of Life of Patients with Advanced Head and Neck Cancers: A Phase 3 Randomized Controlled Trial.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/359594314_Palliative_oral_triple_metronomic_chemotherapy_in_a_patient_with_head-and-neck_cancer_during_the_COVID-19_pandemic_in_India_A_case_report\"><span style=\"font-weight: 400;\">Palliative oral triple metronomic chemotherapy in a patient with head-and-neck cancer during the COVID-19 pandemic in India: A case report.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/337292354_Patterns_of_failure_and_outcomes_in_cT4_Oral_squamous_cell_carcinoma_OSCC_undergoing_upfront_surgery_in_comparison_to_Neo-Adjuvant_Chemotherapy_NACT_followed_by_surgery_A_Matched_Pair_analysis\"><span style=\"font-weight: 400;\">Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysis.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/337067401_DOES_AGE_MATTER_FOR_RADICAL_CHEMORADIATION_IN_HEAD_AND_NECK_CANCER_A_POST-HOC_ANALYSIS_OF_A_RANDOMIZED_STUDY\"><span style=\"font-weight: 400;\">DOES AGE MATTER FOR RADICAL CHEMORADIATION IN HEAD AND NECK CANCER: A POST-HOC ANALYSIS OF A RANDOMIZED STUDY.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/337475910_288OMolecular_profiling_and_treatment_patterns_of_advanced_salivary_gland_cancers_in_head_and_neck_region\"><span style=\"font-weight: 400;\">288OMolecular profiling and treatment patterns of advanced salivary gland cancers in head and neck region.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/336191960_1121PNimotuzumab-cisplatin-radiation_versus_cisplatin-radiation_in_HPV-negative_oropharyngeal_cancer\"><span style=\"font-weight: 400;\">1121PNimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/335964780_Phase_III_Study_of_Palliative_Triple_Metronomic_Chemotherapy_in_Platinum-Refractory_Early-Failure_Oral_Cancer\"><span style=\"font-weight: 400;\">Phase I\/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory\/ Early-Failure Oral Cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/335516736_A_Randomized_Phase_3_Trial_Comparing_Nimotuzumab_Plus_Cisplatin_Chemoradiotherapy_Versus_Cisplatin_Chemoradiotherapy_Alone_in_Locally_Advanced_Head_and_Neck_Cancer\"><span style=\"font-weight: 400;\">A Randomized Phase 3 Trial Comparing Nimotuzumab Plus Cisplatin Chemoradiotherapy Versus Cisplatin Chemoradiotherapy Alone in Locally Advanced Head and Neck Cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/334315515_Taxane-based_Induction_Chemotherapy_Plus_Concurrent_Chemoradiotherapy_in_Nasopharyngeal_Carcinoma_Prospective_Results_from_a_Non-endemic_Cohort\"><span style=\"font-weight: 400;\">Taxane-based Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: Prospective Results from a Non-endemic Cohort.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/334578281_NUT_Midline_Carcinoma\"><span style=\"font-weight: 400;\">NUT Midline Carcinoma.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/334689489_Nimotuzumab_Dosing_and_Outcomes_in_Locally_Advanced_Head_and_Neck_Cancer\"><span style=\"font-weight: 400;\">Nimotuzumab Dosing and Outcomes in Locally Advanced Head and Neck Cancer.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/334895265_Palliative_chemotherapy_in_carcinoma_nasopharynx\"><span style=\"font-weight: 400;\">Palliative chemotherapy in carcinoma nasopharynx.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A-prospective-randomized-phase-II-study-comparing-metronomic-chemotherapy-with-chemotherapy-single-agent-cisplatin-in-patients-with-metastatic-relapse.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Does DeCIDE Give a Decisive Answer Against Induction Chemotherapy in Head and Neck Cancers?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Locoregional recurrences after postoperative Volumetric Modulated Arc Radiotherapy (VMAT) in oral cavity cancers in a resource constrained setting : experience and lessons learned.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Is taxane\/platinum\/5 fluorouracil superior to taxane\/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">How safe is adjuvant RapidArc in Oral Cavity Cancers: An analysis of Marginal and Outfield Failures.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Recurrent sinonasal teratocarcinosarcoma with intracranial extension: Case report.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Weekly chemotherapy as Induction chemotherapy in locally advanced head and neck cancer for patients ineligible for 3 weekly maximum tolerable dose chemotherapy.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Tolerance and toxicity of neoadjuvant docetaxel, cisplatin and 5 fluorouracil regimen in technically unresectable oral cancer in resource limited rural based tertiary cancer center.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A phase II study comparing metronomic chemotherapy with chemotherapy (single-agent cisplatin), in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of head and neck.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neoadjuvant chemotherapy in very locally advanced technically unresectable oral cavity cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">PCN157. Health Related Quality of Life in Patients with Metastatic, Relapsed, or Inoperable Squamous Cell Carcinoma of the Head and Neck in India.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Guidelines for treatment of recurrent or metastatic head and neck cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Referral pattern for neoadjuvant chemotherapy in the head and neck cancers in a tertiary care center.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: A phase III randomised trial.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Epidemiology of oral cancers referred for NACT, the demographics, clinical profile, and organ functions.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Are three drugs better than two and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Acute toxicity of neoadjuvant chemotherapy in oral cavity cancers: Can it be predicted?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">OP048: Induction chemotherapy in unresectable oral cavity cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Oral Metronomic Chemotherapy in Recurrent, Metastatic and Locally Advanced Head and Neck Cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy?.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Development of hyponatremia on neoadjuvant chemotherapy in locally advanced head &amp; neck cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neoadjuvant chemotherapy followed by definitive local treatment in locally advanced carcinoma maxillary sinus.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Palliative chemotherapy in head and neck cancers: A tertiary care center experience with weekly paclitaxel and cetuximab.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Metronomic chemotherapy in advanced oral cancers.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Conformal Radiotherapy in the Treatment of Advanced Juvenile Nasopharyngeal Angiofibroma With Intracranial Extension: An Institutional Experience.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Acute Toxicities Experienced during Simultaneous Integrated Boost Intensity-modulated Radiotherapy in Head and Neck Cancers &#8211; Experience from a North Indian Regional Cancer Centre.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Preliminary results of SIB-IMRT in head and neck cancers: Report from a regional cancer center in northern India.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.researchgate.net\/publication\/333412193_QOL_assessment_in_head_and_neck_cancer_patients_undergoing_neoadjuvant_chemotherapy_and_its_impact_on_overall_survival\"><span style=\"font-weight: 400;\"><span style=\"color: #3366ff;\">QOL assessment in head and neck cancer patients undergoing neoadjuvant chemotherapy and its impact on overall survival.\u00a0<\/span><\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/333412264_A_phase_II_randomized_control_trial_of_erlotinib_in_combination_with_celecoxib_in_patients_with_operable_oral_squamous_cell_carcinoma_OSCC_Erlo-Xib_Study\"><span style=\"font-weight: 400;\">A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/335704312_Dermatofibrosarcoma_protuberans_of_head_and_neck_Clinical_outcome_of_nine_cases_treated_with_imatinib\"><span style=\"font-weight: 400;\">Dermatofibrosarcoma protuberans of head and neck: Clinical outcome of nine cases treated with imatinib.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.researchgate.net\/publication\/392205360_Genomic_Characterization_of_Papillary_Thyroid_Cancer_Reveals_Germline_Mutations_Associated_With_Congenital_Hypothyroidism?_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6Il9kaXJlY3QiLCJwYWdlIjoicHJvZmlsZSJ9fQ\"><span style=\"font-weight: 400;\"><span style=\"color: #3366ff;\">Genomic Characterization of Papillary Thyroid Cancer Reveals Germline Mutations Associated With Congenital Hypothyroidism<\/span><\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/391992666_Triple_Oral_Metronomic_Chemotherapy_Versus_Chemotherapy_of_Physician_Discretion_After_Failure_of_Platinum-Based_Therapy_in_Advanced_Head_and_Neck_Cancer_A_Phase_III_Randomized_Study_METRO-CHASE_Study\"><span style=\"font-weight: 400;\">Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/391992666_Triple_Oral_Metronomic_Chemotherapy_Versus_Chemotherapy_of_Physician_Discretion_After_Failure_of_Platinum-Based_Therapy_in_Advanced_Head_and_Neck_Cancer_A_Phase_III_Randomized_Study_METRO-CHASE_Study\"><span style=\"font-weight: 400;\">Evaluating the prognostic value of tumor-derived circulating endothelial cells and their progenitors in platinum-refractory oral cancer patients for response to triple metronomic therapy<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/391928357_Outcomes_of_selective_neck_dissection_in_node_positive_oral_cavity_squamous_cell_carcinoma\"><span style=\"font-weight: 400;\">Outcomes of selective neck dissection in node positive oral cavity squamous cell carcinoma<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/391197397_PD-L1_in_Oral_Cavity_Cancers-Audit_for_Tertiary_Care_Center_in_India\"><span style=\"font-weight: 400;\">PD-L1 in Oral Cavity Cancers\u2014Audit for Tertiary Care Center in India<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/390617291_Phase_3_randomized_study_of_physician_choice_vs_metronomic_chemotherapy_in_platinum_refractoryineligible_head_and_neck_cancer_in_palliative_setting_with_survival_outcomes\"><span style=\"font-weight: 400;\">Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory\/ineligible head and neck cancer in palliative setting with survival outcomes<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/390617291_Phase_3_randomized_study_of_physician_choice_vs_metronomic_chemotherapy_in_platinum_refractoryineligible_head_and_neck_cancer_in_palliative_setting_with_survival_outcomes\"><span style=\"font-weight: 400;\">Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory\/ineligible head and neck cancer in palliative setting with survival outcomes<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/389475223_Ewing's_Sarcoma_of_the_Head_and_Neck_Outcomes_of_101_Patients_Treated_at_a_Tertiary_Cancer_Center\"><span style=\"font-weight: 400;\">Ewing&#8217;s Sarcoma of the Head and Neck: Outcomes of 101 Patients Treated at a Tertiary Cancer Center<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/388945554_Compartmentalization_of_High_Infratemporal_Fossa_in_Oral_Cavity_Squamous_Cell_Carcinomas_and_Its_Impact_on_Clinical_Outcome\"><span style=\"font-weight: 400;\">Compartmentalization of High Infratemporal Fossa in Oral Cavity Squamous Cell Carcinomas and Its Impact on Clinical Outcome<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/386070744_Nose_and_sinuses\"><span style=\"font-weight: 400;\">Nose and sinuses<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/385982911_Indian_clinical_practice_consensus_guidelines_for_the_management_of_nasopharyngeal_cancer_-_Update_2023\"><span style=\"font-weight: 400;\">Indian clinical practice consensus guidelines for the management of nasopharyngeal cancer<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/385985007_Indian_clinical_practice_consensus_guidelines_for_the_management_of_locoregional_hypopharyngeal_cancer_-_Update_2023\"><span style=\"font-weight: 400;\">Indian clinical practice consensus guidelines for the management of locoregional hypopharyngeal cancer &#8211; Update 2023<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/393784863_Comprehensive_Genomic_Profiling_of_Anaplastic_Thyroid_Cancer_Identifies_Alterations_in_THRA_a_Potential_Modifier_of_Cellular_Plasticity\"><span style=\"font-weight: 400;\">Comprehensive Genomic Profiling of Anaplastic Thyroid Cancer Identifies Alterations in THRA, a Potential Modifier of Cellular Plasticity<\/span><\/a><\/span><\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2f93080e elementor-widget__width-auto elementor-widget elementor-widget-n-accordion\" data-id=\"2f93080e\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-7980\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-7980\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Neuro <\/div><\/span>\n\t\t\t\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-7980\" class=\"elementor-element elementor-element-78525a15 e-con-full e-flex e-con e-child\" data-id=\"78525a15\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-050e6a5 elementor-widget elementor-widget-text-editor\" data-id=\"050e6a5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ol><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/362507630_MMAP-08_CHEMO-REIRRADIATION_NORMOFRACTIONATED_VS_HYPOFRACTIONATED_WITH_OR_WITHOUT_BEVACIZUMAB_IN_RECURRENT_ADULT_DIFFUSE_HIGH-GRADE_GLIOMA_COBRA_PHASE_III_RANDOMIZED_CONTROLLED_TRIAL_WITH_A_2_X_2_FACT\"><span style=\"font-weight: 400;\">MMAP-08 CHEMO-REIRRADIATION (NORMOFRACTIONATED VS. HYPOFRACTIONATED) WITH OR WITHOUT BEVACIZUMAB IN RECURRENT ADULT DIFFUSE HIGH-GRADE GLIOMA (COBRA): PHASE III RANDOMIZED CONTROLLED TRIAL WITH A 2 X 2 FACTORIAL DESIGN.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/360899322_Mebendazole_plus_lomustine_or_temozolomide_in_patients_with_recurrent_glioblastoma_A_randomised_open-label_phase_II_trial\"><span style=\"font-weight: 400;\">Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361077577_MEDB-27_Clinico-Radiological_Outcomes_in_WNT-pathway_Medulloblastoma_Retrospective_Single_Institutional_Audit\"><span style=\"font-weight: 400;\">MEDB-27. Clinico-Radiological Outcomes in WNT-pathway Medulloblastoma: Retrospective Single Institutional Audit.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361123210_Efficacy_of_Gemcitabine_in_recurrent_meningioma_A_phase_II_study\"><span style=\"font-weight: 400;\">Efficacy of Gemcitabine in recurrent meningioma: A phase II study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/361317771_High-dose_salvage_re-irradiation_in_recurrentprogressive_adult_diffuse_gliomas_development_of_a_novel_prognostic_scoring_system\"><span style=\"font-weight: 400;\">High-dose salvage re-irradiation in recurrent\/progressive adult diffuse gliomas: development of a novel prognostic scoring system.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/360451848_Efficacy_and_safety_of_extended_adjuvant_temozolomide_compared_to_standard_adjuvant_temozolomide_in_glioblastoma_updated_systematic_review_and_meta-analysis\"><span style=\"font-weight: 400;\">Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/359856852_Diffuse_hemispheric_glioma_H3G34-mutant_distinctive_clinicopathological_features\"><span style=\"font-weight: 400;\">Diffuse hemispheric glioma, H3G34-mutant: distinctive clinicopathological features.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/359856854_Optimizing_adjuvant_therapy_in_elderly_patients_with_glioblastoma_single-institution_audit_of_outcomes\"><span style=\"font-weight: 400;\">Optimizing adjuvant therapy in elderly patients with glioblastoma: single-institution audit of outcomes.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/359801563_The_prevalence_of_cognitive_impairment_in_older_Indian_persons_with_cancer_and_brain_metastases\"><span style=\"font-weight: 400;\">The prevalence of cognitive impairment in older Indian persons with cancer and brain metastases.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/358006855_Prognostic_impact_of_semantic_MRI_features_on_survival_outcomes_in_molecularly_subtyped_medulloblastoma\"><span style=\"font-weight: 400;\">Prognostic impact of semantic MRI features on survival outcomes in molecularly subtyped medulloblastoma.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/357898346_Temozolomide-induced_myelotoxicity_and_single_nucleotide_polymorphisms_in_the_MGMT_gene_in_patients_with_adult_diffuse_glioma_a_single-institutional_pharmacogenetic_study\"><span style=\"font-weight: 400;\">Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/358730982_Optimizing_Postoperative_Adjuvant_Therapy_in_Elderly_Patients_with_Newly_Diagnosed_Glioblastoma_Single-Institution_Audit_of_Clinical_Outcomes_from_a_Tertiary-Care_Comprehensive_Cancer_Center_in_India\"><span style=\"font-weight: 400;\">Optimizing Postoperative Adjuvant Therapy in Elderly Patients with Newly Diagnosed Glioblastoma: Single-Institution Audit of Clinical Outcomes from a Tertiary-Care Comprehensive Cancer Center in India.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/358835852_Definitive_and_adjuvant_radiation_therapy_for_external_auditory_canal_and_temporal_bone_squamous_cell_carcinomas_Long_term_outcomes\"><span style=\"font-weight: 400;\">Definitive and adjuvant radiation therapy for external auditory canal and temporal bone squamous cell carcinomas: Long term outcomes.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.researchgate.net\/publication\/348539624_Cost-Effectiveness_of_Temozolamide_for_Treatment_of_Glioblastoma_Multiforme_in_India\"><span style=\"font-weight: 400;\"><span style=\"color: #3366ff;\">Cost-Effectiveness of Temozolamide for Treatment of Glioblastoma Multiforme in India.<\/span>\u00a0<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Expectation and Preferences with Palliative Systemic Therapy in Recurrent Gliomas<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The story of two eyes- What to look for in the patient&#8217;s eyes?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">RTHP-01. DOES THE EFFICACY OF SALVAGE RE-IRRADIATION IN RECURRENT MEDULLOBLASTOMA DEPEND UPON RISK-STRATIFICATION, SITE OF RELAPSE, AND MOLECULAR SUBGROUP?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and Vomiting in Patients with Glioma<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">RONC-17. DOES THE EFFICACY OF SALVAGE RE-IRRADIATION IN RECURRENT MEDULLOBLASTOMA DEPEND UPON RISK-STRATIFICATION, SITE OF RELAPSE, AND MOLECULAR SUBGROUP?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">RONC-07. THE TALE OF 100 DIPGs AND RADIOTHERAPY<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/356351293_CTNI-34_TOXICITY_PROFILE_AND_COMPLIANCE_OF_PATIENTS_WITH_HIGH_RISK_GRADE_2_OR_GRADE_3_GLIOMAS_RECEIVING_ADJUVANT_PCV_VERSUS_ADJUVANT_TEMOZOLOMIDE\"><span style=\"font-weight: 400;\">CTNI-34. TOXICITY PROFILE AND COMPLIANCE OF PATIENTS WITH HIGH RISK GRADE 2 OR GRADE 3 GLIOMAS RECEIVING ADJUVANT PCV VERSUS ADJUVANT TEMOZOLOMIDE.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/353892602_Brain_FET_PET_tumor-to-white_mater_ratio_to_differentiate_recurrence_from_post-treatment_changes_in_high-grade_gliomas\"><span style=\"font-weight: 400;\">Brain FET PET tumor\u2010to\u2010white mater ratio to differentiate recurrence from post\u2010treatment changes in high\u2010grade gliomas.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/353812107_Prognostic_Impact_of_Semantic_MRI_Features_on_Survival_Outcomes_in_Medulloblastoma_Does_It_Reflect_or_Transcend_Radiogenomic_Correlation\"><span style=\"font-weight: 400;\">Prognostic Impact of Semantic MRI Features on Survival Outcomes in Medulloblastoma: Does It Reflect or Transcend Radiogenomic Correlation?.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/353207076_Optimal_dose_of_bevacizumab_in_recurrent_glioma_A_retrospective_study\"><span style=\"font-weight: 400;\">Optimal dose of bevacizumab in recurrent glioma: A retrospective study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/353099575_Upfront_Therapy_of_AggressiveHigh-Risk_Low-Grade_Glioma_Single-Institution_Outcome_Analysis_of_Temozolomide-Based_Radio-Chemotherapy_and_Adjuvant_Chemotherapy\"><span style=\"font-weight: 400;\">Upfront Therapy of Aggressive\/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/352292097_High-dose_Salvage_Re-irradiation_in_Recurrentprogressive_Adult_Diffuse_High-Grade_Glioma_Development_of_a_Novel_Prognostic_Scoring_System\"><span style=\"font-weight: 400;\">High-dose Salvage Re-irradiation in Recurrent\/progressive Adult Diffuse High-Grade Glioma: Development of a Novel Prognostic Scoring System.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/352071589_The_prevalence_of_cognitive_impairment_in_older_Indian_persons_with_cancer_and_brain_metastases\"><span style=\"font-weight: 400;\">The prevalence of cognitive impairment in older Indian persons with cancer and brain metastases.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/352089418_MGMT_gene_polymorphisms_in_patients_with_severe_hematological_toxicity_treated_with_temozolomide_for_adult_diffuse_gliomas_Results_from_a_tertiary-care_comprehensive_cancer_center\"><span style=\"font-weight: 400;\">MGMT gene polymorphisms in patients with severe hematological toxicity treated with temozolomide for adult diffuse gliomas: Results from a tertiary-care comprehensive cancer center.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/351085226_Clinical_Audit_of_Survival_Outcomes_and_Prognostic_Factors_in_Adolescents_and_Adults_with_Medulloblastoma\"><span style=\"font-weight: 400;\">Clinical Audit of Survival Outcomes and Prognostic Factors in Adolescents and Adults with Medulloblastoma.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/350400810_Cancer-related_fatigue_and_its_impact_on_quality_of_life_in_patients_with_central_nervous_system_tumors_A_cross-sectional_analysis\"><span style=\"font-weight: 400;\">Cancer-related fatigue and its impact on quality of life in patients with central nervous system tumors: A cross-sectional analysis.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/349026534_Safety_and_efficacy_of_concurrent_carboplatin_during_full-dose_craniospinal_irradiation_for_high-riskmetastatic_medulloblastoma_in_a_resource-limited_setting\"><span style=\"font-weight: 400;\">Safety and efficacy of concurrent carboplatin during full-dose craniospinal irradiation for high-risk\/metastatic medulloblastoma in a resource-limited setting.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/348974521_High-dose_salvage_re-irradiation_for_recurrentprogressive_adult_diffuse_glioma_healing_or_hurting\"><span style=\"font-weight: 400;\">High-dose salvage re-irradiation for recurrent\/progressive adult diffuse glioma: healing or hurting?.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/348442641_Safety_and_efficacy_of_bevacizumab_biosimilar_in_recurrent_progressive_glioblastoma\"><span style=\"font-weight: 400;\">Safety and efficacy of bevacizumab biosimilar in recurrent\/ progressive glioblastoma.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/347909109_Financial_toxicities_in_patients_receiving_systemic_therapy_for_brain_tumors_A_cross-sectional_study\"><span style=\"font-weight: 400;\">Financial toxicities in patients receiving systemic therapy for brain tumors: A cross-sectional study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/346074764_Thromboembolic_events_in_brain_tumour_patients_on_bevacizumab\"><span style=\"font-weight: 400;\">Thromboembolic events in brain tumour patients on bevacizumab.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/346740526_Multidisciplinary_brain_metastasis_clinic_is_it_effective_and_worthwhile\"><span style=\"font-weight: 400;\">Multidisciplinary brain metastasis clinic: is it effective and worthwhile?.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/352360136_A_Survey_of_Satisfaction_with_Treatment_among_Brain_Tumor_Patients\"><span style=\"font-weight: 400;\">A Survey of Satisfaction with Treatment among Brain Tumor Patients.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/352429281_Gemcitabine_in_Recurrent_Meningioma\"><span style=\"font-weight: 400;\">Gemcitabine in Recurrent Meningioma.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/344413174_391P_Cognitive_impairment_in_primary_brain_tumour_patients_receiving_systemic_therapy_A_cross-sectional_study\"><span style=\"font-weight: 400;\">391P Cognitive impairment in primary brain tumour patients receiving systemic therapy: A cross-sectional study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/344312170_Cognitive_score_in_patients_with_primary_brain_tumors_undergoing_systemic_therapy_-_a_cross-sectional_study\"><span style=\"font-weight: 400;\">Cognitive score in patients with primary brain tumors undergoing systemic therapy \u2013 a cross-sectional study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/344283274_SPIRITUAL_WELL-BEING_IN_BRAIN_TUMOUR_PATIENTS_-AN_INSIGHT\"><span style=\"font-weight: 400;\">SPIRITUAL WELL-BEING IN BRAIN TUMOUR PATIENTS -AN INSIGHT.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/344375387_Financial_toxicity_in_patients_undergoing_systemic_therapy_in_brain_tumours_A_cross-sectional_study\"><span style=\"font-weight: 400;\">Financial toxicity in patients undergoing systemic therapy in brain tumours: A cross-sectional study.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/344202785_Prospective_Longitudinal_Assessment_of_Quality_of_Life_and_Activities_of_Daily_Living_as_Patient-Reported_Outcome_Measures_in_Recurrent_Progressive_Glioma_Treated_with_High-dose_Salvage_Re-irradiation\"><span style=\"font-weight: 400;\">Prospective Longitudinal Assessment of Quality of Life and Activities of Daily Living as Patient-Reported Outcome Measures in Recurrent\/ Progressive Glioma Treated with High-dose Salvage Re-irradiation.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/345372448_390P_Spiritual_well-being_in_brain_tumour_patients_An_insight\"><span style=\"font-weight: 400;\">390P Spiritual well-being in brain tumour patients: An insight.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/343584381_Extended_adjuvant_temozolomide_in_newly_diagnosed_glioblastoma_Is_more_less\"><span style=\"font-weight: 400;\">Extended adjuvant temozolomide in newly diagnosed glioblastoma: Is more less?.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341677174_Melanotic_Schwannoma_a_Deceptive_Misnomer_for_a_Tumor_With_Relative_Aggressive_Behavior_A_Series_of_7_Cranial_and_Spinal_Cases\"><span style=\"font-weight: 400;\">Melanotic Schwannoma, a Deceptive Misnomer for a Tumor With Relative Aggressive Behavior: A Series of 7 Cranial and Spinal Cases.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341629799_Safety_and_efficacy_of_bevacizumab_biosimilar_in_glioma\"><span style=\"font-weight: 400;\">Safety and efficacy of bevacizumab biosimilar in glioma.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/341351326_Reverse_swing-M_phase_1_study_of_repurposing_mebendazole_in_recurrent_high-grade_glioma\"><span style=\"font-weight: 400;\">Reverse swing\u2010M, phase 1 study of repurposing mebendazole in recurrent high\u2010grade glioma.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/338597937_Differentiating_dural_metastases_from_meningioma_role_of_68Ga_DOTA-NOC_PETCT\"><span style=\"font-weight: 400;\">Differentiating dural metastases from meningioma: role of 68Ga DOTA-NOC PET\/CT.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/343004593_Coronavirus_disease_2019_pandemic_and_its_implications_on_triaging_patients_with_brain_tumors_for_surgery_radiotherapy_and_chemotherapy\"><span style=\"font-weight: 400;\">Coronavirus disease 2019 pandemic and its implications on triaging patients with brain tumors for surgery, radiotherapy, and chemotherapy.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P09.03 Bevacizumab in glioma: An experience from Tata Memorial Hospital<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Rechallenge temozolomide in glioma: A case series from India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A case series of salvage CCNU in high-grade glioma who have previously received temozolomide from a tertiary care institute in Mumbai<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation)<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.researchgate.net\/publication\/337475484_57PMultidisciplinary_brain_metastasis_clinic_Is_it_effective_and_worthwhile\"><span style=\"font-weight: 400;\"><span style=\"color: #3366ff;\">PMultidisciplinary brain metastasis clinic: Is it effective and worthwhile?.\u00a0<\/span><\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/337475492_59PPattern_of_care_in_high-grade_gliomas_after_recurrence\"><span style=\"font-weight: 400;\">PPattern of care in high-grade gliomas after recurrence.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Shielding in whole brain irradiation in the multileaf collimator era: Dosimetric evaluation of coverage using SFOP guidelines against in-house guidelines<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.researchgate.net\/publication\/334011874_Outcomes_of_salvage_re-irradiation_in_recurrent_medulloblastoma_correlate_with_age_at_initial_diagnosis_primary_risk-stratification_and_molecular_subgrouping\"><span style=\"font-weight: 400;\"><span style=\"color: #3366ff;\">Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping.\u00a0<\/span><\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/334894949_An_exceptional_response_to_nivolumab_in_relapsed_and_refractory_malignant_mesothelioma\"><span style=\"font-weight: 400;\">An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/334894964_Neoadjuvant_chemotherapy_in_technically_unresectable_adenocarcinoma_of_parotid\"><span style=\"font-weight: 400;\">Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid.\u00a0<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/333212365_EP-1235_Response_to_re-RT_helps_deciding_dose_and_predicts_survival_in_Diffuse_Intrinsic_Pontine_Glioma\"><span style=\"font-weight: 400;\">EP-1235 Response to re-RT helps deciding dose and predicts survival in Diffuse Intrinsic Pontine Glioma.\u00a0<\/span><\/a><\/span><\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-302955e8 elementor-widget__width-auto elementor-widget elementor-widget-n-accordion\" data-id=\"302955e8\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-8080\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-8080\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Thoracic <\/div><\/span>\n\t\t\t\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-8080\" class=\"elementor-element elementor-element-2d183f8a e-con-full e-flex e-con e-child\" data-id=\"2d183f8a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2298dbdb elementor-widget__width-inherit elementor-widget-tablet__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"2298dbdb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ol><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">EP08.03-002 Local Ablative Therapy in Oligoprogressive NSCLC &#8211; Results from a Tertiary Cancer Center of India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Leptomeningeal metastasis from non-small cell lung cancer \u2013 a post-hoc analysis from four randomised clinical trials<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Phase III randomized controlled trial comparing chemotherapy to best supportive care in advanced esophageal and gastroesophageal junction cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Five years survival outcomes of head and neck cancer patients treated with palliative metronomic chemotherapy.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Checkpoint inhibitor accessibility in 15,000+ Indian patients.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Long-term outcomes of a randomized controlled clinical trial comparing the efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Small cell carcinoma of the oesophagus: experience of an Indian Tertiary Cancer Centre<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Tackling brain metastases from lung cancer during the COVID\u201019 pandemic<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">EGFR exon 20 insertion in non-small cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Molecular tumor board: Case 1-Interplay of EGFR, MET and PD-L1 in non-small cell lung carcinoma<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Desperate times, desperate measures: Low-dose nivolumab-induced remission in relapsed NSCLC<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">LBA10A randomized investigator initiated phase III study comparing low dose gemcitabine to standard dose gemcitabine with platinum in advanced squamous non driver mutated non-small cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">529PThe management and outcome of crizotinib resistant patients: Comparison of patients who received ceritinib to those treated with chemotherapy or other oral TKI<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: A prospective observational study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P2-122Retrospective study to evaluate treatment outcomes of Pleural Mesothelioma treated in a tertiary care centre from India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">MA02.07 Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P2.01-54 Predictive Factors for Thromboembolism in Advanced Lung Cancer Patients on Platinum Chemotherapy: A Prospective Study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P1.01-44 Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced NSCLC Patients: A Single-Centre Retrospective Analysis<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Tyrosine Kinase Inhibitor versus Physician Choice Chemotherapy in Second-Line Epidermal Growth Factor Receptor Mutation Non-Small Cell Lung Cancer: Post hoc Analysis of Randomized Control Trial<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Quality of life analysis of Pemetrexed versus Erlotinib maintenance in EGFR mutation negative advanced non small cell lung cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Impact of imaging based sarcopenia and modified advanced lung cancer inflammation index (mALI) on clinical outcomes in advanced NSCLC: A occult killer and a prognostic biomarker.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Molecular tumor board\u2013guided treatment of non-small-cell lung cancer with dual driver (ALK and EGFR) alterations<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Efficacy and safety of induction weekly paclitaxel and carboplatin in esophageal cancer: A retrospective study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Epidemiological Trend of Esophageal Cancer in Mumbai, India, Over the Past Fifteen Years<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Post-cricoid and Upper Oesophagus Cancers Treated with Organ Preservation Using Intensity-modulated Image-guided Radiotherapy: a Phase II Prospective Study of Outcomes, Toxicity and Quality of Life<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">PO-0957 Organ-preservation in Post-Cricoid and Upper-Esophagus (PCUE) cancers: Seeking optimum outcomes<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Small Cell Carcinoma Esophagus: Experience of an Indian Tertiary Cancer Center<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The epidemiological trend of esophageal cancer in Mumbai, India over the past two decades.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Pulmonary sarcomatoid carcinoma: Retrospective analysis from a single center.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Impact of the geriatric assessment on clinical treatment decision in older Indian persons with cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Distress Screening in Head and Neck Cancer Patients Planned for Cancer\u2010Directed Radiotherapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: A study protocol of phase III randomised controlled trial<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P76.26 Survival Outcomes in Patients Receiving Second Line Osimertinib Post First Line First Generation TKI Alone or in Combination with Chemotherapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A randomized clinical trial evaluating the efficacy and safety of the addition of oral metronomic chemotherapy after completion of standard chemoradiation versus observation in patients with locally advanced esophageal and gastroesophageal junction squamous cell carcinoma.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast\u2013ovarian cancer syndrome<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">165P Analysis of our experience of ROS-1 patients in advanced NSCLC<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">417P Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">403P Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non\u2013small cell lung cancer (NSCLC) with brain metastases<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Systemic therapy for limited stage small cell lung carcinoma<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The role of chemotherapy in patients with small cell lung cancer and poor performance status View supplementary material The role of chemotherapy in patients with small cell lung cancer and poor performance status<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Resistance mechanisms to epidermal growth factor receptor inhibitors in non-small cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Deep learning-based predictive imaging biomarker model for EGFR mutation status in non-small cell lung cancer from CT imaging.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Leptomeningeal metastasis from non-small cell lung cancer- outcomes from a tertiary care center.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Definitive Radiation Therapy With Dose Escalation Is Beneficial In Patients With Squamous Cell Cancer Of The Esophagus<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Reply to T. Tanaka et al and F. Liang<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Systemic therapy for thoracic malignancies during the COVID-19 pandemic<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Radiologic progression in a patient with non-small-cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The efficacy and safety of first-line therapy for the epidermal growth factor receptor mutant non-small cell lung cancer in older versus younger patients: A pooled analysis of two randomized controlled trials<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neurological deterioration in a patient with lung cancer and brain metastasis<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">151P Maintenance therapy using tyrosine kinase inhibitor (erlotinib) or pemetrexed in metastatic\/locally advanced in EGFR mutation-negative lung cancer: Comparison of results<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">72PD MR imaging radiomics of NSCLC brain metastases: A potential targetable imaging biomarker for EGFR status<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Applying the QUARTZ Trial Results in Clinical Practice: Development of a Prognostic Model Predicting Poor Outcomes for Non-small Cell Lung Cancers with Brain Metastases<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Prognostic value of a patient-reported functional score versus physician-reported Karnofsky Performance Status Score in brain metastases<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P3.03-015 ROS-1 Rearranged Non-Small Cell Lung Cancer and Crizotinib: An Indian Experience<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P2.03-027 Comparative Longitudinal Toxicity Analysis of EGFR Mutated NSCLC Treated with Either Pemetrexed Carboplatin or Gefitinib<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P2.01-051 Randomized Study of Pemetrexed Versus Erlotinib as Maintenance Therapy in Metastatic \/Locally Advanced EGFR Mutation Negative NSCLC<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P3.01-076 QTWiST Analysis to Compare the Benefit of Gefitinib Versus Pemetrexed Platinum for Patients with EGFR Mutated NSCLC<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P1.03-021 A Prospective Observational Study to Evaluate Incidence of Thromboembolic Events during Platinum Based Chemotherapy in Lung Cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P1.01-021 FISH and IHC Discordance in ALK Rearranged Non-Small Cell Lung Cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P1.01-024 Plasma Circulating cfDNA as a Potential Biomarker in Clinical Management of NSCLC: Experience of Tata Memorial Hospital, India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P1.01-023 ALK-Positive NSCLC: A TMH Experience<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">PUB059 Gefitinib Versus Pemetrexed-Platinum Therapy in EGFR Activating Mutated Lung Cancer: Impact on Brain Metastasis<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">432PQTWiST analysis to compare the benefit of maintenance Erlotinib versus pemetrexed patients with EGFR non mutated NSCLC<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3\u20134) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Comparison of paclitaxel-cetuximab chemotherapy versus metronomic chemotherapy consisting of methotrexate and celecoxib as palliative chemotherapy in head and neck cancers<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed\u2013carboplatin chemotherapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">1294PReal world data of practice patterns and outcomes for pemetrexed plus platinum as neoadjuvant chemotherapy in adenocarcinomas of lung from a tertiary cancer center of India: Looking beyond the usual paradigm<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Bayesian relative survival : An illustration with lung cancer patients data<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Assess the Feasibility of Introducing Early Palliative Care in Ambulatory Patients with Advanced Lung Cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Epidermal growth factor receptor exon 20 mutation in lung cancer: Types, incidence, clinical features and impact on treatment<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">EGFR testing scenario across 111 centres in India: A questionnaire-based survey.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Feasibility and outcome of repeat biopsy upon progression on tyrosine kinase inhibitors in patients with EGFR mutation positive adenocarcinoma of lung-an Indian tertiary cancer centre experience.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Reference Data for Standardized Quality of Life Questionnaires in Indian Patients with Brain Metastases from Non-small Cell Lung Cancer: Results from a Prospective Study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">ROS1 rearranged nonsmall cell lung cancer and crizotinib: An Indian experience<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Drug-sensitive FGFR3 mutations in lung adenocarcinoma<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">EGFR mutation in squamous cell carcinoma of the lung: Does it carry the same connotation as in adenocarcinomas?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P3.02b-007 Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P3.02b-065 Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P3.02b-090 Pemetrexed versus Gefitinib in EGFR Mutation Positive Lung Cancer: Results of a Phase 3 Study from India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P3.02b-094 Rebiopsy Post Progression in EGFR Mutated Lung Cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">PUB118 Pre-Chemotherapy EGFR Mutation Status &amp; Outcomes with Second Line Gefitinib in Advanced Adenocarcinoma Lung<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P3.02b-055 Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P3.02b-058 Second-Line Therapy in EGFR Activating Mutation Positive Advanced NSCLC: Analysis from a Randomized Phase III First-Line Trial<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Ceritinib in anaplastic lymphoma kinase-positive nonsmall cell lung cancer among patients who were previously exposed to crizotinib: Experience from the Indian subcontinent<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Epidermal growth factor receptor positive lung cancer: The nontrial scenario<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Expanded panel test detecting mesenchymal-epithelial transition amplification leading to effective treatment in adenocarcinoma lung<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Chandrani et al. suppl Methods and Figures 20161110<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Chandrani et al. Supplementary Tables 20161110<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Aggressive Surgery in Palliative Setting of Lung Cancer: Is it Helpful?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">EGFR mutation in squamous cell carcinoma of lung &#8211; Does it carry the same connotation as in adenocarcinomas?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung Cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Lung cancer in the Indian subcontinent<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Effect of EGFR mutations on outcomes in NSCLC with brain metastases.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Curative intent therapy in oligometastatic lung cancer with an unresectable primary with N3 nodes: case report and review of the literature<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">175P ALK positive lung cancer: Clinical profile and outcomes in a developing country<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Epidermal Growth Factor Receptor Mutation in Small Cell Lung Cancer Patients in an Indian Tertiary Care Oncology Hospital: Incidence and Clinical Outcome<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">3051 Relevance of performance status as a prognosticator in EGFR mutant NSCLC<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A cross sectional retrospective study regarding patients and their physician willingness to wait for driver mutation report in NSCLC.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The importance of brain metastasis in EGFR mutation positive NSCLC patients<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Induction Chemotherapy in Locally Advanced Pharyngolaryngeal Cancers with Stridor: Is It Feasible and Safe?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Baby-step chemotherapy as a way to deliver chemotherapy in poor PS small cell lung cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">177PReal-world experience of ALK positive NSCLC from India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">55ORadiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P1.01-88 PS 2 Patients with Advanced EGFR Mutant NSCLC: Subset Analysis of a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P2.01-102 Outcome of Patients with EGFR Exon 19 Mutation in a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed\/ carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: A single center retrospective analysis<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">ROS1 mutation non-small cell lung cancer\u2014access to optimal treatment and outcomes<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/393784863_Comprehensive_Genomic_Profiling_of_Anaplastic_Thyroid_Cancer_Identifies_Alterations_in_THRA_a_Potential_Modifier_of_Cellular_Plasticity\"><span style=\"font-weight: 400;\">Assessment of plasma derived microbiome profiles in lung cancer using targeted and whole exome sequencing<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/391372663_Defining_the_role_of_pragmatic_clinical_trials_in_cancer_clinical_research_outcomes_of_a_collaborative_workshop_hosted_by_the_European_Organisation_for_Research_and_Treatment_of_Cancer\"><span style=\"font-weight: 400;\">Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/390479606_Safety_and_Efficacy_of_Alectinib_in_the_First_Line_for_ALK-Mutated_Lung_Cancer_A_Real-World_Data_from_India\"><span style=\"font-weight: 400;\">Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/390479606_Safety_and_Efficacy_of_Alectinib_in_the_First_Line_for_ALK-Mutated_Lung_Cancer_A_Real-World_Data_from_India\"><span style=\"font-weight: 400;\">Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/389895576_The_impact_of_co-occurring_tumor_suppressor_mutations_with_mEGFR_as_early_indicators_of_relapse_in_lung_cancer\"><span style=\"font-weight: 400;\">The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/389643985_Clinical_characteristics_and_first-line_palliative_treatment_patterns_in_3414_patients_with_advanced_lung_cancer_in_India\"><span style=\"font-weight: 400;\">Clinical characteristics and first-line palliative treatment patterns in 3,414 patients with advanced lung cancer in India<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/389475075_Pleuropulmonary_Blastoma_Outcomes_of_Patients_Treated_with_Curative_Intent_Protocols\"><span style=\"font-weight: 400;\">Pleuropulmonary Blastoma: Outcomes of Patients Treated with Curative Intent Protocols<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/389475220_Unilateral_Retinoblastoma_Audit_of_Outcomes_of_Children_treated_with_Curative_Treatment_Protocol\"><span style=\"font-weight: 400;\">Unilateral Retinoblastoma: Audit of Outcomes of Children treated with Curative Treatment Protocol<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/388855628_A_Novel_Deep_Learning-Based_3D_U-Net_Model_Automated_Pulmonary_Nodule_Detection_Tool_for_CT_Imaging\"><span style=\"font-weight: 400;\">A Novel Deep Learning-Based (3D U-Net Model) Automated Pulmonary Nodule Detection Tool for CT Imaging<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/386172565_Pregabalin_for_chronic_cough_due_to_lung_cancer_randomized_double-blind_placebo-controlled_trial\"><span style=\"font-weight: 400;\">Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/386022767_Deep_Diving_Into_the_Fusion_Across_Cancer_Types_in_the_Indian_Population_From_Formalin-Fixed_Paraffin-Embedded_RNA-Exome_Data_A_Road_to_Discovering_Novel_Rearrangements_With_Clinical_Relevance\"><span style=\"font-weight: 400;\">Deep Diving Into the Fusion Across Cancer Types in the Indian Population From Formalin-Fixed Paraffin-Embedded RNA-Exome Data: A Road to Discovering Novel Rearrangements With Clinical Relevance<\/span><\/a><\/span><\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-47f1c316 elementor-widget__width-auto elementor-widget elementor-widget-n-accordion\" data-id=\"47f1c316\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1200\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1200\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Uro <\/div><\/span>\n\t\t\t\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1200\" class=\"elementor-element elementor-element-26503f73 e-con-full e-flex e-con e-child\" data-id=\"26503f73\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5f156883 elementor-widget__width-inherit elementor-widget-tablet__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"5f156883\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ol><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">214P Study of treatment outcome in adults with TFE related RCC<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A competing risk analysis of death patterns in male genitourinary cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">P.14.50 Clinicopathological spectrum of intracranial germ cell tumors: an Indian tertiary cancer center experience<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Metastatic Renal Cell Cancer\u2014Systemic Therapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Epidemiology of male seminomatous (SGCT) and non-seminomatous germ cell tumours (NSGCT) and response to first line chemotherapy (CT) from a tertiary cancer centre in India.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Sunitinib in metastatic renal cell carcimoma: A single-center experience<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer<\/span><\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3f68429e elementor-widget__width-auto elementor-widget elementor-widget-n-accordion\" data-id=\"3f68429e\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1060\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1060\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> GI <\/div><\/span>\n\t\t\t\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1060\" class=\"elementor-element elementor-element-2820d198 e-con-full e-flex e-con e-child\" data-id=\"2820d198\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-21b6cdc7 elementor-widget__width-inherit elementor-widget-tablet__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"21b6cdc7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ol><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Role of palliative chemotherapy and targeted therapy in advanced esophageal and gastroesophageal junction cancers<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Outcomes with Palliative Weekly Paclitaxel in Advanced, Recurrent, and Metastatic Esophageal Cancer &#8211; Real World Experience<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Efficacy and Safety of Induction Chemotherapy in Esophageal Cancer with Airway Involvement<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Metronomics in low and middle income countries: India showing the way!<\/span><\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-11c9e32 elementor-widget__width-auto elementor-widget elementor-widget-n-accordion\" data-id=\"11c9e32\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1860\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1860\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Others <\/div><\/span>\n\t\t\t\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1860\" class=\"elementor-element elementor-element-f542dac e-con-full e-flex e-con e-child\" data-id=\"f542dac\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e6264c0 elementor-widget__width-inherit elementor-widget-tablet__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"e6264c0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ol><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Demographics, Outcomes, Prognostic Factors in Adolescent-Adult Non-metastatic Ewing&#8217;s Sarcomas- Experience from a Tertiary Cancer Center in India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Outcomes of Ewing sarcoma in adults over 40 years of age from a low-middle income country<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">G8 and VES-13 as screening tools for geriatric assessment and predictors of survival in older Indian patients with cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Vascular endothelial growth factor as a potential prognosticator in Ewing Sarcoma: a tertiary care cancer center experience from India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Testing and interpreting assumptions of COX regression analysis<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Author Reply to: Sahoo, Batra et al. and Mullapally et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Survey for geriatric assessment in practicing oncologists in India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with solid neoplasms: A real-world experience from a tertiary cancer center<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Caregiver burden in older Indian patients with cancer- Experience from a tertiary care center<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Prevalence and outcomes of frailty in older patients with cancer: A prospective study from geriatric oncology clinic.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Geriatric assessment as a predictor of survival among older Indian patients with cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Comprehensive Development and Implementation of Good Laboratory Practice for NGS Based Targeted Panel on Solid Tumor FFPE Tissues in Diagnostics<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Actionable Activating Oncogenic ERRB2\/HER2 Transmembrane and Juxtamembrane Domain Mutations<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Effect of mastitis on lactation curves in purebred Jersey cows<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Diagnostic quandary over a cheek(y) neoplasm<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Supplementary Material<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Strategic approaches to overcome resistance against Gram negative pathogens using \u03b2-lactamase inhibitors and \u03b2-lactam enhancers: The activity of three novel diazabicyclooctanes, WCK 5153, zidebactam (WCK 5107), and WCK 4234<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">\u201cThe clinical utility and safety of Short\u2010course Immune check point inhibitors ( ICI ) in multiple tumors \u2010 A real world multicentric study from India\u201d<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Deviation from standard cancer treatment during the first wave of the COVID-19 pandemic in India: A cross-sectional study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Optical and structural characterization of high crystalline \u03b2-Ga2O3 films prepared using an RF magnetron sputtering<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas &#8211; Experience From a Tertiary Cancer Centre in India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">1705P The correlation of the ECOG performance status with vulnerabilities in the geriatric assessment: A retrospective cohort study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Comparison of validated screening tools for the assessment of potentially inappropriate medications in older Indian patients with cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The use of G8 and VES13 as screening and prognostic tools in older Indian patients with cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Caregiver burden in older Indian patients with cancer: Experience from a tertiary care center.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Accuracy of the CARG chemotherapy toxicity risk prediction tool in older Indian patients with cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Adolescent-adult nonmetastatic Ewing sarcoma-Experience from a large developing country<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Impact of sex of the patient on efficacy and safety of cancer immunotherapy: A retrospective audit<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A real-world data of Immune checkpoint inhibitors in solid tumors from India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Adolescent-Adult Non-metastatic Ewing Sarcoma- Experience from a large developing country<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Rare case of Skene gland adenocarcinoma with RET- rearrangement<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Polypharmacy and potentially inappropriate medication use in older Indian patients with cancer: A prospective observational study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Algorithm to choose the appropriate test for comparison between two groups<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; reply to Patel, Gupta et al., and Jha et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors\u2019 reply to Divya et al<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors\u2019 reply to Dhanushkodi et al. and Chalissery<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">COVID-19 in cancer patients on active systemic therapy &#8211; Outcomes from LMIC scenario with an emphasis on need for active treatment<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Lymphopenia during chemoradiation\u2014foe or friend<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Appendix I Quartz Paper CO submission Revised<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Table S1<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Table S3<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Supplementary Figure 1<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Table S2<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Agreement analysis between three different short geriatric screening scales in patients undergoing chemotherapy for solid tumors<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">390PLiquid biopsies in clinical oncology: Review of validation results<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents: Noronha et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Supplementary Data<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Bayesian accelerated failure time and its application in Chemotherapy drug treatment trial<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Determining an Optimum Biological Dose of A Metronomic Chemotherapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">biyoistatistik8-2-1<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Next generation metronomic chemotherapy\u2014report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6\u20138 May 2016, Mumbai<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Clinico-pathological Study of Limb Salvage Surgery for Osteosarcoma: Experience in a Rural Cancer Center<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Weekly cisplatin (30\u201340 mg\/m2) as radiosensitizer: Is it high or moderate emetic agent?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Utility of driver mutation<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Phase III open label randomized controlled trial comparing intravenous iron sucrose to oral ferrous sulphate (without erythropoiesis stimulating agents) in the treatment of cancer related iron deficiency anemia.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Survey of implementation of antiemetic prescription standards in Indian oncology practices and adherence to ASCO&#8217;s antiemetic clinical guideline.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Development and validation of a questionnaire to measure preferences and expectations of patients undergoing palliative chemotherapy: EXPECT questionnaire<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Concordance of epidermal growth factor receptor mutation detection in bodily fluids other than blood with tissue biopsy: A retrospective analysis<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Efficacy and safety of low dose immunotherapy in palliative setting of advanced solid tumours<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">1049P Efficacy and safety of low dose immunotherapy in palliative setting of advanced solid tumours<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">An audit of cytoreductive surgeries in ovarian cancer from a rural based cancer center<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Predictivity of human papillomavirus positivity in advanced oral cancer<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Association of immune-related adverse effects and survival in responders treated with immune checkpoint inhibitors.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">CancerResStatTreat3515-2728831 073448<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Abstract A28: Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: Retrospective data from real-world settings<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Extent of re-excision, sequence\/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent\/progressive ependymoma<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; reply to Kulkarni et al. and Wiwanitkit<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Retrospective audit of clinico-pathologic features and treatment outcomes in a cohort of elderly non-Hodgkin&#8217;s lymphoma patients in a tertiary cancer center<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Survey of the State of Implementation of the American Society of Clinical Oncology\/Oncology Nursing Society Safety Standards for Chemotherapy Administration in India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Burden and Outcomes of Pressure Ulcers in Cancer Patients Receiving the Kerala Model of Home Based Palliative Care in India: Results From a Prospective Observational Study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dessai et al-2014-Psycho-Oncology<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Pelvic Exenteration: Experience from a Rural CancerCenter in Developing World<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; reply to Krishnamurthy, Bhosale et al., and Mohan et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; reply to Dubey et al. and Bhattacharyya et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; reply to Jiwnani et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Metronomics: The next generation of multitargeted therapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">An audit of febrile neutropenia cases from a rural cancer center in India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Pattern of infection, therapy, outcome and risk stratification of patients with febrile neutropenia in a tertiary care oncology hospital in India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Magnitude and Implications of Interfraction Variations in Organ Doses during High Dose Rate Brachytherapy of Cervix Cancer: A CT Based Planning Study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Predicting complications of chemotherapy-induced febrile neutropenia: A single-center experience.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Metronomic therapy: Chemotherapy revisited<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Patterns of care in geriatric cancer patients \u2013 An audit from a rural based hospital cancer registry in Kerala<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Pilot study of single-day distress screening with the NCCN distress thermometer to evaluate the feasibility of routine distress screening in tertiary cancer center in rural India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">How well do Elderly patients with cervical cancer tolerate definitive radiochemotherapy using RapidArc? Results from an institutional audit comparing elderly versus younger patients<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Exploring the role of systemic therapy in adult adrenocortical carcinoma: A single-center experience<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Leptomeningeal metastasis from extracranial solid tumors<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; reply to Vora et al. and Singh et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Initial experience of a geriatric oncology clinic in a tertiary cancer center in India<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; reply to Daddi<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Skin rash: Disease or drug?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; reply to Chandrasekharan et al. and Abbas<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cytomegalovirus infection in solid malignancies<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; reply to Kumar et al. and Kannan et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cancer thrombosis: Narrative review<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; reply to Kies and Katna et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; response to Vora and Rajpurohit<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Authors&#8217; reply to Batra et al., Chadha et al., and Deb et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Author&#8217;s reply to Tripathi et al. and Memon et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">THE COMPREHENSIVE GERIATRIC PROFILE OF INDIAN ONCOLOGY PATIENTS: EXPERIENCE OF A GERIATRIC ONCOLOGY CLINIC IN A TERTIARY CANCER CENTER IN INDIA<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">DPYD Mutation in Indian Patients<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Author Reply to Kapoor et al.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Effect of parity on the shape of lactation curves in purebred Jersey cows in Indian conditions<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Effect of growth variables on properties of gallium oxide thin films grown by sputtering<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Effects of post-growth annealing in vacuum and Zn vapor on the electrical and optical properties of magnetron sputtered GaMgZnO films<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Single Agent Weekly Paclitaxel as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Feasibility Study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Can point doses predict volumetric dose to rectum and bladder: A CT-based planning study in high dose rate intracavitary brachytherapy of cervical carcinoma?<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dosimetric risk estimates of radiation-induced malignancies after intensity modulated radiotherapy<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Supplementary Material 1<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Supplementary Material 2<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Appendix 5<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Chiral Separation and Thermodynamic Investigation of WCK 3023: A Novel Oxazolidinone Antibacterial Agent, Application to Pre\u2010clinical Pharmacokinetic Study<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Author response to: Reducing dexamethasone premedication with paclitaxel<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Low doses in immunotherapy: Are they effective?<\/span><\/li><\/ol><ol><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/393784863_Comprehensive_Genomic_Profiling_of_Anaplastic_Thyroid_Cancer_Identifies_Alterations_in_THRA_a_Potential_Modifier_of_Cellular_Plasticity\">Comprehensive Genomic Profiling of Anaplastic Thyroid Cancer Identifies Alterations in THRA, a Potential Modifier of Cellular Plasticity<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/393784863_Comprehensive_Genomic_Profiling_of_Anaplastic_Thyroid_Cancer_Identifies_Alterations_in_THRA_a_Potential_Modifier_of_Cellular_Plasticity\">Assessment of plasma derived microbiome profiles in lung cancer using targeted and whole exome sequencing<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/392205360_Genomic_Characterization_of_Papillary_Thyroid_Cancer_Reveals_Germline_Mutations_Associated_With_Congenital_Hypothyroidism?_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6Il9kaXJlY3QiLCJwYWdlIjoicHJvZmlsZSJ9fQ\">Genomic Characterization of Papillary Thyroid Cancer Reveals Germline Mutations Associated With Congenital Hypothyroidism<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/391992666_Triple_Oral_Metronomic_Chemotherapy_Versus_Chemotherapy_of_Physician_Discretion_After_Failure_of_Platinum-Based_Therapy_in_Advanced_Head_and_Neck_Cancer_A_Phase_III_Randomized_Study_METRO-CHASE_Study\">Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/391992666_Triple_Oral_Metronomic_Chemotherapy_Versus_Chemotherapy_of_Physician_Discretion_After_Failure_of_Platinum-Based_Therapy_in_Advanced_Head_and_Neck_Cancer_A_Phase_III_Randomized_Study_METRO-CHASE_Study\"> Evaluating the prognostic value of tumor-derived circulating endothelial cells and their progenitors in platinum-refractory oral cancer patients for response to triple metronomic therapy<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/391372663_Defining_the_role_of_pragmatic_clinical_trials_in_cancer_clinical_research_outcomes_of_a_collaborative_workshop_hosted_by_the_European_Organisation_for_Research_and_Treatment_of_Cancer\">Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer <\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/391928357_Outcomes_of_selective_neck_dissection_in_node_positive_oral_cavity_squamous_cell_carcinoma\">Outcomes of selective neck dissection in node positive oral cavity squamous cell carcinoma<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/391197397_PD-L1_in_Oral_Cavity_Cancers-Audit_for_Tertiary_Care_Center_in_India\">PD-L1 in Oral Cavity Cancers\u2014Audit for Tertiary Care Center in India<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/390479606_Safety_and_Efficacy_of_Alectinib_in_the_First_Line_for_ALK-Mutated_Lung_Cancer_A_Real-World_Data_from_India\">Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/390479606_Safety_and_Efficacy_of_Alectinib_in_the_First_Line_for_ALK-Mutated_Lung_Cancer_A_Real-World_Data_from_India\">Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/390617291_Phase_3_randomized_study_of_physician_choice_vs_metronomic_chemotherapy_in_platinum_refractoryineligible_head_and_neck_cancer_in_palliative_setting_with_survival_outcomes\">Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory\/ineligible head and neck cancer in palliative setting with survival outcomes<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/390617291_Phase_3_randomized_study_of_physician_choice_vs_metronomic_chemotherapy_in_platinum_refractoryineligible_head_and_neck_cancer_in_palliative_setting_with_survival_outcomes\">Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory\/ineligible head and neck cancer in palliative setting with survival outcomes<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/389895576_The_impact_of_co-occurring_tumor_suppressor_mutations_with_mEGFR_as_early_indicators_of_relapse_in_lung_cancer\">The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/389643985_Clinical_characteristics_and_first-line_palliative_treatment_patterns_in_3414_patients_with_advanced_lung_cancer_in_India\">Clinical characteristics and first-line palliative treatment patterns in 3,414 patients with advanced lung cancer in India<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/389475075_Pleuropulmonary_Blastoma_Outcomes_of_Patients_Treated_with_Curative_Intent_Protocols\">Pleuropulmonary Blastoma: Outcomes of Patients Treated with Curative Intent Protocols<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/389475220_Unilateral_Retinoblastoma_Audit_of_Outcomes_of_Children_treated_with_Curative_Treatment_Protocol\">Unilateral Retinoblastoma: Audit of Outcomes of Children treated with Curative Treatment Protocol<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/389475223_Ewing's_Sarcoma_of_the_Head_and_Neck_Outcomes_of_101_Patients_Treated_at_a_Tertiary_Cancer_Center\">Ewing&#8217;s Sarcoma of the Head and Neck: Outcomes of 101 Patients Treated at a Tertiary Cancer Center<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/388945554_Compartmentalization_of_High_Infratemporal_Fossa_in_Oral_Cavity_Squamous_Cell_Carcinomas_and_Its_Impact_on_Clinical_Outcome\">Compartmentalization of High Infratemporal Fossa in Oral Cavity Squamous Cell Carcinomas and Its Impact on Clinical Outcome<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/388855628_A_Novel_Deep_Learning-Based_3D_U-Net_Model_Automated_Pulmonary_Nodule_Detection_Tool_for_CT_Imaging\">A Novel Deep Learning-Based (3D U-Net Model) Automated Pulmonary Nodule Detection Tool for CT Imaging<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/386172565_Pregabalin_for_chronic_cough_due_to_lung_cancer_randomized_double-blind_placebo-controlled_trial\">Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/386070744_Nose_and_sinuses\">Nose and sinuses<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/386022767_Deep_Diving_Into_the_Fusion_Across_Cancer_Types_in_the_Indian_Population_From_Formalin-Fixed_Paraffin-Embedded_RNA-Exome_Data_A_Road_to_Discovering_Novel_Rearrangements_With_Clinical_Relevance\">Deep Diving Into the Fusion Across Cancer Types in the Indian Population From Formalin-Fixed Paraffin-Embedded RNA-Exome Data: A Road to Discovering Novel Rearrangements With Clinical Relevance<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/385982911_Indian_clinical_practice_consensus_guidelines_for_the_management_of_nasopharyngeal_cancer_-_Update_2023\">Indian clinical practice consensus guidelines for the management of nasopharyngeal cancer<\/a><\/span><\/li><li><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/www.researchgate.net\/publication\/385985007_Indian_clinical_practice_consensus_guidelines_for_the_management_of_locoregional_hypopharyngeal_cancer_-_Update_2023\">Indian clinical practice consensus guidelines for the management of locoregional hypopharyngeal cancer &#8211; Update 2023<\/a><\/span><\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<\/p>                        <\/div>\n\n                    <\/div>\n\n                <\/div><!-- .elementskit-card END -->\n\n                                        <\/div>\n    <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-93ffc74 elementor-widget elementor-widget-text-editor\" data-id=\"93ffc74\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><i><span style=\"font-weight: 400;\">\u201cLet science serve people, not the other way around.\u201d<\/span><\/i><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-858a4eb elementor-widget elementor-widget-text-editor\" data-id=\"858a4eb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">To consult with Dr. (Prof.) Vijay Patil or explore SunAct\u2019s advanced oncology programs, visit<\/span><span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/regisdigitals.com\/client\/Sunact\/contact\"> <span style=\"font-weight: 400;\">sunactcancer.com\/contact<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Co-founder, SUNACT Specialist in Solid Tumors &amp; Advanced Cancer Therapies Dr. (Prof.) Vijay Patil Transforming cancer care through innovation, accessibility, and compassion. About Dr. Patil Dr. (Prof.) Vijay Patil is a distinguished medical oncologist with over 2 decades of clinical and research experience, specializing in the management of solid tumors and the development of next-generation [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-3804","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/pages\/3804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/comments?post=3804"}],"version-history":[{"count":0,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/pages\/3804\/revisions"}],"wp:attachment":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/media?parent=3804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}